var nodeData = [
  {
    "x": 2019.5833,
    "y": 100,
    "r": 3141,
    "category": 7,
    "company": "AbbVie",
    "dates_clean": "2019-08-16",
    "brand_name": "Rinvoq",
    "condition": "Rheumatoid Arthritis",
    "description": "Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor for the treatment of adult patients with moderate to severe rheumatoid arthritis.",
    "middle_radius": 1571,
    "inner_radius": 1041
  },
  {
    "x": 2019.25,
    "y": 100,
    "r": 1305,
    "category": 7,
    "company": "AbbVie",
    "dates_clean": "2019-04-23",
    "brand_name": "Skyrizi",
    "condition": "Plaque Psoriasis",
    "description": "Skyrizi (risankizumab-rzaa) is an interleukin-23 (IL-23) inhibitor for the treatment of plaque psoriasis.",
    "middle_radius": 300,
    "inner_radius": 300
  },
  {
    "x": 2017.5833,
    "y": 100,
    "r": 2589,
    "category": 6,
    "company": "AbbVie",
    "dates_clean": "2017-08-03",
    "brand_name": "Mavyret",
    "condition": "Chronic Hepatitis C",
    "description": "Mavyret (glecaprevir/pibrentasvir) is a fixed-dose combination of glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an NS5A inhibitor, indicated for the treatment of all major genotypes (GT1-6) of chronic hepatitis C.",
    "middle_radius": 116,
    "inner_radius": 0
  },
  {
    "x": 2016.25,
    "y": 100,
    "r": 106,
    "category": 7,
    "company": "AbbVie",
    "dates_clean": "2016-04-11",
    "brand_name": "Venclexta",
    "condition": "Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia",
    "description": "Venclexta (venetoclax) is an oral B-cell lymphoma-2 (BCL-2) inhibitor indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2014.9167,
    "y": 100,
    "r": 2308,
    "category": 6,
    "company": "AbbVie",
    "dates_clean": "2014-12-19",
    "brand_name": "Viekira Pak",
    "condition": "Chronic Hepatitis C",
    "description": "Viekira Pak (ombitasvir/paritaprevir/ritonavir with dasabuvir) is an NS5A inhibitor, NS3/4A protease inhibitor and CYP3A inhibitor combination co-packaged with a non-nucleoside NS5B palm polymerase inhibitor for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection.",
    "middle_radius": 255,
    "inner_radius": 255
  },
  {
    "x": 2018.5,
    "y": 100,
    "r": 1664,
    "category": 10,
    "company": "AbbVie",
    "dates_clean": "2018-07-23",
    "brand_name": "Orilissa",
    "condition": "Endometriosis",
    "description": "Orilissa (elagolix) is an orally administered gonadotropin-releasing hormone (GnRH) antagonist for the management of moderate to severe pain associated with endometriosis.",
    "middle_radius": 726,
    "inner_radius": 726
  },
  {
    "x": 2016.3333,
    "y": 100,
    "r": 2253,
    "category": 7,
    "company": "AbbVie and Biogen",
    "dates_clean": "2016-05-27",
    "brand_name": "Zinbryta",
    "condition": "Multiple Sclerosis",
    "description": "Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS).",
    "middle_radius": 1126,
    "inner_radius": 204
  },
  {
    "x": 2019.0833,
    "y": 100,
    "r": 145,
    "category": 3,
    "company": "Ablynx NV",
    "dates_clean": "2019-02-06",
    "brand_name": "Cablivi",
    "condition": "Acquired Thrombotic Thrombocytopenic Purpura",
    "description": "Cablivi (caplacizumab-yhdp) is a von Willebrand factor (vWF)-directed antibody fragment indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.",
    "middle_radius": 73,
    "inner_radius": 73
  },
  {
    "x": 2016.25,
    "y": 100,
    "r": 185,
    "category": 1,
    "company": "Acadia Pharmaceuticals",
    "dates_clean": "2016-04-29",
    "brand_name": "Nuplazid",
    "condition": "Parkinsonäó»s Disease Psychosis",
    "description": "Nuplazid (pimavanserin) is a non-dopaminergic, selective serotonin inverse agonist (SSIA) for the treatment of psychosis associated with Parkinsonäó»s disease.",
    "middle_radius": 90,
    "inner_radius": 90
  },
  {
    "x": 2018.4167,
    "y": 100,
    "r": 406,
    "category": 6,
    "company": "Achaogen",
    "dates_clean": "2018-06-25",
    "brand_name": "Zemdri",
    "condition": "Urinary Tract Infection",
    "description": "Zemdri (plazomicin) is an aminoglycoside antibacterial for the treatment of complicated urinary tract infections.",
    "middle_radius": 208,
    "inner_radius": 0
  },
  {
    "x": 2010,
    "y": 100,
    "r": 540,
    "category": 1,
    "company": "Acorda Therapeutics",
    "dates_clean": "2010-01-22",
    "brand_name": "Ampyra",
    "condition": "Multiple Sclerosis",
    "description": "Ampyra (dalfampridine) is an oral potassium channel blocker indicated to improve walking ability in people with multiple sclerosis.",
    "middle_radius": 191,
    "inner_radius": 191
  },
  {
    "x": 2015.0833,
    "y": 100,
    "r": 0,
    "category": 6,
    "company": "Actavis",
    "dates_clean": "2015-02-25",
    "brand_name": "Avycaz",
    "condition": "Intraabdominal Infection, Urinary Tract Infection, Pneumonia",
    "description": "Avycaz (avibactam and ceftazidime) is a next generation, non-‘_ lactam ‘_-lactamase inhibitor and third-generation, antipseudomonal cephalosporin antibiotic combination for the treatment of complicated intra-abdominal infections, complicated urinary tract infections, hospital-acquired bacterial pneumonia, and ventilator-associated bacterial pneumonia.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2013.75,
    "y": 100,
    "r": 742,
    "category": 4,
    "company": "Actelion Pharmaceuticals",
    "dates_clean": "2013-10-18",
    "brand_name": "Opsumit",
    "condition": "Pulmonary Hypertension",
    "description": "Opsumit (macitentan) is a dual endothelin receptor antagonist for the treatment of patients with pulmonary arterial hypertension.",
    "middle_radius": 250,
    "inner_radius": 250
  },
  {
    "x": 2015.9167,
    "y": 100,
    "r": 1156,
    "category": 3,
    "company": "Actelion Pharmaceuticals",
    "dates_clean": "2015-12-21",
    "brand_name": "Uptravi",
    "condition": "Pulmonary Arterial Hypertension",
    "description": "Uptravi (selexipag) is an oral prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension.",
    "middle_radius": 582,
    "inner_radius": 582
  },
  {
    "x": 2018,
    "y": 100,
    "r": 589,
    "category": 10,
    "company": "Advanced Accelerator Applications",
    "dates_clean": "2018-01-26",
    "brand_name": "Lutathera",
    "condition": "Gastroenteropancreatic Neuroendocrine Tumors",
    "description": "Lutathera (lutetium Lu 177 dotatate) is a Lu-177-labeled somatostatin analogue indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.",
    "middle_radius": 113,
    "inner_radius": 0
  },
  {
    "x": 2012.9167,
    "y": 100,
    "r": 23799,
    "category": 3,
    "company": "Aegerion Pharmaceuticals",
    "dates_clean": "2012-12-21",
    "brand_name": "Eliquis",
    "condition": "Homozygous Familial Hypercholesterolemia",
    "description": "Eliquis (apixaban) is a factor Xa inhibitor anticoagulant indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the prophylaxis of deep vein thrombosis (DVT) in patients who have undergone hip or knee replacement surgery.",
    "middle_radius": 11872,
    "inner_radius": 0
  },
  {
    "x": 2019.1667,
    "y": 100,
    "r": 1468,
    "category": 10,
    "company": "Aerie Pharmaceuticals",
    "dates_clean": "2019-03-12",
    "brand_name": "Rocklatan",
    "condition": "Glaucoma (Open Angle), Intraocular Hypertension",
    "description": "Rocklatan (netarsudil and latanoprost ophthalmic solution) is a fixed dose combination of the Rho kinase inhibitor netarsudil (Rhopressa) and the prostaglandin F2‘± analogue latanoprost (Xalatan), indicated to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.",
    "middle_radius": 969,
    "inner_radius": 0
  },
  {
    "x": 2017.9167,
    "y": 100,
    "r": 881,
    "category": 10,
    "company": "Aerie Pharmaceuticals",
    "dates_clean": "2017-12-18",
    "brand_name": "Rhopressa",
    "condition": "Glaucoma",
    "description": "Rhopressa (netarsudil ophthalmic solution) is a Rho kinase inhibitor for the treatment of open-angle glaucoma or ocular hypertension.\r\r\r\r",
    "middle_radius": 453,
    "inner_radius": 0
  },
  {
    "x": 2017.9167,
    "y": 100,
    "r": 140,
    "category": 10,
    "company": "Aeterna Zentaris",
    "dates_clean": "2017-12-20",
    "brand_name": "Macrilen",
    "condition": "Diagnosis of Adult Growth Hormone Deficiency",
    "description": "Macrilen (macimorelin) is a growth hormone (GH) secretagogue receptor agonist indicated for the diagnosis of adult growth hormone deficiency.",
    "middle_radius": 81,
    "inner_radius": 81
  },
  {
    "x": 2012.1667,
    "y": 100,
    "r": 1608,
    "category": 3,
    "company": "Affymax and Takeda",
    "dates_clean": "2012-03-27",
    "brand_name": "Omontys",
    "condition": "Anemia Associated with Chronic Renal Failure",
    "description": "Omontys (peginesatide) an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis.",
    "middle_radius": 542,
    "inner_radius": 0
  },
  {
    "x": 2018.5,
    "y": 100,
    "r": 174,
    "category": 7,
    "company": "Agios Pharmaceuticals",
    "dates_clean": "2018-07-20",
    "brand_name": "Tibsovo",
    "condition": "Acute Myeloid Leukemia",
    "description": "Tibsovo (ivosidenib) is an isocitrate dehydrogenase-1 (IDH1) inhibitor for the treatment of patients with acute myeloid leukemia who have an IDH1 mutation.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2014.9167,
    "y": 100,
    "r": 686,
    "category": 6,
    "company": "Alcon Laboratories",
    "dates_clean": "2014-12-17",
    "brand_name": "Xtoro",
    "condition": "Otitis Externa",
    "description": "Xtoro (finafloxacin otic suspension) is a fluoroquinolone antimicrobial for the treatment of acute otitis externa, commonly known as swimmeräó»s ear.",
    "middle_radius": 342,
    "inner_radius": 342
  },
  {
    "x": 2018.9167,
    "y": 100,
    "r": 441,
    "category": 7,
    "company": "Alexion Pharmaceuticals",
    "dates_clean": "2018-12-21",
    "brand_name": "Ultomiris",
    "condition": "Paroxysmal Nocturnal Hemoglobinuria, Hemolytic Uremic Syndrome",
    "description": "Ultomiris (ravulizumab-cwvz) is a long-acting C5 complement inhibitor for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).",
    "middle_radius": 219,
    "inner_radius": 0
  },
  {
    "x": 2015.75,
    "y": 100,
    "r": 81,
    "category": 2,
    "company": "Alexion Pharmaceuticals",
    "dates_clean": "2015-10-23",
    "brand_name": "Strensiq",
    "condition": "Hypophosphatasia",
    "description": "Strensiq (asfotase alfa) is a tissue nonspecific alkaline phosphatase  enzyme replacement therapy indicated for the treatment of patients with perinatal, infantile and juvenile-onset hypophosphatasia (HPP).\r\r",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2015.9167,
    "y": 100,
    "r": 9,
    "category": 2,
    "company": "Alexion Pharmaceuticals",
    "dates_clean": "2015-12-08",
    "brand_name": "Kanuma",
    "condition": "Lysosomal Acid Lipase Deficiency",
    "description": "Kanuma (sebelipase alfa) is an enzyme replacement therapy for the treatment of lysosomal acid lipase deficiency (LAL-D).",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2015.75,
    "y": 100,
    "r": 622,
    "category": 1,
    "company": "Alkermes",
    "dates_clean": "2015-10-05",
    "brand_name": "Aristada",
    "condition": "Schizophrenia",
    "description": "Aristada (aripiprazole lauroxil) is an extended-release injectable atypical antipsychotic with one-month, six-week, and two-month dosing options for the treatment of schizophrenia.",
    "middle_radius": 207,
    "inner_radius": 207
  },
  {
    "x": 2015.6667,
    "y": 100,
    "r": 1466,
    "category": 1,
    "company": "Allergan and Gedeon Richter",
    "dates_clean": "2015-09-17",
    "brand_name": "Vraylar",
    "condition": "Schizophrenia, Bipolar Disorder",
    "description": "Vraylar (cariprazine) is a dopamine D3/D2 receptor partial agonist atypical antipsychotic for the treatment of schizophrenia and bipolar mania.",
    "middle_radius": 442,
    "inner_radius": 442
  },
  {
    "x": 2019.9167,
    "y": 100,
    "r": 2797,
    "category": 1,
    "company": "Allergan",
    "dates_clean": "2019-12-23",
    "brand_name": "ubrelvy",
    "condition": "Migraine",
    "description": "Ubrelvy (ubrogepant) is a potent, orally-administered CGRP receptor antagonist for the acute treatment of migraine.",
    "middle_radius": 1122,
    "inner_radius": 1122
  },
  {
    "x": 2015.3333,
    "y": 100,
    "r": 2425,
    "category": 2,
    "company": "Allergan",
    "dates_clean": "2015-05-27",
    "brand_name": "Viberzi",
    "condition": "Irritable Bowel Syndrome",
    "description": "Viberzi (eluxadoline) is a mu-opioid receptor agonist indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.",
    "middle_radius": 809,
    "inner_radius": 809
  },
  {
    "x": 2015.25,
    "y": 100,
    "r": 1022,
    "category": 5,
    "company": "Allergan",
    "dates_clean": "2015-04-29",
    "brand_name": "Kybella",
    "condition": "Submental Fullness",
    "description": "Kybella (deoxycholic acid) is a cytolytic drug indicated to improve the appearance of fullness associated with submental fat (double chin).",
    "middle_radius": 508,
    "inner_radius": 508
  },
  {
    "x": 2014.3333,
    "y": 100,
    "r": 1312,
    "category": 6,
    "company": "Allergan",
    "dates_clean": "2014-05-23",
    "brand_name": "Dalvance",
    "condition": "Skin and Structure Infection",
    "description": "Dalvance (dalbavancin) is a second generation lipoglycopeptide antibiotic for the treatment of adult patients with complicated skin and skin structure infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).",
    "middle_radius": 653,
    "inner_radius": 0
  },
  {
    "x": 2012.5833,
    "y": 100,
    "r": 2458,
    "category": 2,
    "company": "Allergan",
    "dates_clean": "2012-08-30",
    "brand_name": "Linzess",
    "condition": "Irritable Bowel Syndrome, Constipation -- Chronic",
    "description": "Linzess (linaclotide) is a guanylate cyclase-C agonist indicated in adults for treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).",
    "middle_radius": 1222,
    "inner_radius": 1222
  },
  {
    "x": 2012.5,
    "y": 100,
    "r": 1276,
    "category": 9,
    "company": "Allergan",
    "dates_clean": "2012-07-23",
    "brand_name": "Tudorza",
    "condition": "Chronic Obstructive Pulmonary Disease",
    "description": "Tudorza Pressair (aclidinium bromide inhalation powder) is an anticholinergic indicated for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.",
    "middle_radius": 640,
    "inner_radius": 640
  },
  {
    "x": 2011.0833,
    "y": 100,
    "r": 9481,
    "category": 9,
    "company": "Allergan",
    "dates_clean": "2011-02-28",
    "brand_name": "Daliresp",
    "condition": "Chronic Obstructive Pulmonary Disease",
    "description": "Daliresp (roflumilast) is an orally administered phosphodiesterase 4 (PDE4) enzyme inhibitor indicated as a treatment to reduce the risk of COPD  exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.",
    "middle_radius": 4204,
    "inner_radius": 4204
  },
  {
    "x": 2011,
    "y": 100,
    "r": 869,
    "category": 1,
    "company": "Allergan",
    "dates_clean": "2011-01-21",
    "brand_name": "Viibryd",
    "condition": "Depression",
    "description": "Viibryd (vilazodone) is a dual-acting potent and selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist indicated for the treatment of major depressive disorder (MDD).",
    "middle_radius": 433,
    "inner_radius": 433
  },
  {
    "x": 2010.75,
    "y": 100,
    "r": 1105,
    "category": 6,
    "company": "Allergan",
    "dates_clean": "2010-10-29",
    "brand_name": "Teflaro",
    "condition": "Pneumonia, Skin and Structure Infection",
    "description": "Teflaro (ceftaroline fosamil) is a cephalosporin antibacterial indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).",
    "middle_radius": 552,
    "inner_radius": 0
  },
  {
    "x": 2010.5,
    "y": 100,
    "r": 488,
    "category": 10,
    "company": "Allergan",
    "dates_clean": "2010-07-28",
    "brand_name": "Lastacaft",
    "condition": "Allergic Conjunctivitis",
    "description": "Lastacaft (alcaftadine ophthalmic solution) is a topical H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis.",
    "middle_radius": 247,
    "inner_radius": 247
  },
  {
    "x": 2018.75,
    "y": 100,
    "r": 2002,
    "category": 6,
    "company": "Almirall",
    "dates_clean": "2018-10-01",
    "brand_name": "Seysara",
    "condition": "Acne",
    "description": "Seysara (sarecycline) is an oral, narrow spectrum tetracycline-derived antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.",
    "middle_radius": 1000,
    "inner_radius": 1000
  },
  {
    "x": 2019.8333,
    "y": 100,
    "r": 94,
    "category": 2,
    "company": "Alnylam Pharmaceuticals",
    "dates_clean": "2019-11-20",
    "brand_name": "Givlaari",
    "condition": "Acute Hepatic Porphyria",
    "description": "Givlaari (givosiran) is an aminolevulinate synthase 1-directed small interfering RNA (siRNA) indicated for the treatment of adults with acute hepatic porphyria (AHP).",
    "middle_radius": 46,
    "inner_radius": 46
  },
  {
    "x": 2018.5833,
    "y": 100,
    "r": 225,
    "category": 1,
    "company": "Alnylam Pharmaceuticals",
    "dates_clean": "2018-08-10",
    "brand_name": "Onpattro",
    "condition": "Hereditary Transthyretin-Mediated Amyloidosis (hATTR)",
    "description": "Onpattro (patisiran) is a small interfering ribonucleic acid (siRNA) therapeutic  for the treatment of polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR).",
    "middle_radius": 77,
    "inner_radius": 77
  },
  {
    "x": 2019.4167,
    "y": 100,
    "r": 1198,
    "category": 10,
    "company": "AMAG Pharmaceuticals",
    "dates_clean": "2019-06-21",
    "brand_name": "Vyleesi",
    "condition": "Hypoactive Sexual Desire Disorder",
    "description": "Vyleesi  (bremelanotide) is a melanocortin receptor agonist for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.",
    "middle_radius": 603,
    "inner_radius": 603
  },
  {
    "x": 2019.25,
    "y": 100,
    "r": 11273,
    "category": 8,
    "company": "Amgen",
    "dates_clean": "2019-04-09",
    "brand_name": "Evenity",
    "condition": "Osteoporosis",
    "description": "Evenity (romosozumab) is an anti-sclerostin monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.",
    "middle_radius": 5638,
    "inner_radius": 3591
  },
  {
    "x": 2018.3333,
    "y": 100,
    "r": 2199,
    "category": 1,
    "company": "Amgen",
    "dates_clean": "2018-05-17",
    "brand_name": "Aimovig",
    "condition": "Migraine Prophylaxis",
    "description": "Aimovig (erenumab-aooe) is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the preventive treatment of migraine.\r\r",
    "middle_radius": 896,
    "inner_radius": 896
  },
  {
    "x": 2017.0833,
    "y": 100,
    "r": 1023,
    "category": 10,
    "company": "Amgen",
    "dates_clean": "2017-02-07",
    "brand_name": "Parsabiv",
    "condition": "Secondary Hyperparathyroidism",
    "description": "Parsabiv (etelcalcetide) is a calcium-sensing receptor agonist indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.",
    "middle_radius": 514,
    "inner_radius": 514
  },
  {
    "x": 2015.5833,
    "y": 100,
    "r": 813,
    "category": 4,
    "company": "Amgen",
    "dates_clean": "2015-08-27",
    "brand_name": "Repatha",
    "condition": "High Cholesterol; Prevention of Heart Attack and Stroke",
    "description": "Repatha (evolocumab) is a monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) indicated for the treatment of patients with heterozygous familial hypercholesterolemia; homozygous familial hypercholesterolemia; and to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease.",
    "middle_radius": 255,
    "inner_radius": 255
  },
  {
    "x": 2015.25,
    "y": 100,
    "r": 6505,
    "category": 4,
    "company": "Amgen",
    "dates_clean": "2015-04-15",
    "brand_name": "Corlanor",
    "condition": "Chronic Heart Failure",
    "description": "Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated for the treatment of chronic heart failure.",
    "middle_radius": 3264,
    "inner_radius": 3264
  },
  {
    "x": 2014.9167,
    "y": 100,
    "r": 185,
    "category": 7,
    "company": "Amgen",
    "dates_clean": "2014-12-03",
    "brand_name": "Blincyto",
    "condition": "Acute Lymphoblastic Leukemia",
    "description": "Blincyto (blinatumomab) is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), and minimal residual disease (MRD)-positive B-cell precursor ALL.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2012.5,
    "y": 100,
    "r": 266,
    "category": 7,
    "company": "Amgen",
    "dates_clean": "2012-07-20",
    "brand_name": "Kyprolis",
    "condition": "Multiple Myeloma",
    "description": "Kyprolis (carfilzomib) is a proteasome inhibitor indicated for the treatment of patients with multiple myeloma.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2010.8333,
    "y": 100,
    "r": 7808,
    "category": 8,
    "company": "Amgen",
    "dates_clean": "2010-11-18",
    "brand_name": "Xgeva",
    "condition": "Osteolytic Bone Metastases of Solid Tumors, Osteolytic Bone Lesions of Multiple Myeloma, Giant Cell Tumor of Bone, Hypercalcemia of Malignancy",
    "description": "Xgeva (denosumab) is a RANK ligand (RANKL) inhibitor indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. Xgeva is also indicated for treatment giant cell tumor of bone and for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.",
    "middle_radius": 3906,
    "inner_radius": 3906
  },
  {
    "x": 2010.4167,
    "y": 100,
    "r": 7393,
    "category": 8,
    "company": "Amgen",
    "dates_clean": "2010-06-01",
    "brand_name": "Prolia",
    "condition": "Osteoporosis",
    "description": "Prolia is a RANK ligand (RANKL) inhibitor indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, for the treatment of bone loss in patients with prostate or breast cancer undergoing hormone ablation therapy, as a treatment to increase bone mass in men with osteoporosis at high risk for fracture, and for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture.",
    "middle_radius": 3691,
    "inner_radius": 3691
  },
  {
    "x": 2018.5833,
    "y": 100,
    "r": 45,
    "category": 2,
    "company": "Amicus Therapeutics",
    "dates_clean": "2018-08-10",
    "brand_name": "Galafold",
    "condition": "Fabry Disease",
    "description": "Galafold (migalastat) is an alpha-galactosidase A (alpha-Gal A) pharmacological chaperone indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant.",
    "middle_radius": 20,
    "inner_radius": 20
  },
  {
    "x": 2014.0833,
    "y": 100,
    "r": 48,
    "category": 2,
    "company": "Amylin Pharmaceuticals",
    "dates_clean": "2014-02-24",
    "brand_name": "Myalept",
    "condition": "Lipodystrophy",
    "description": "Myalept (metreleptin) is a leptin analog indicated to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2014.5,
    "y": 100,
    "r": 1194,
    "category": 5,
    "company": "Anacor Pharmaceuticals",
    "dates_clean": "2014-07-07",
    "brand_name": "Kerydin",
    "condition": "Onychomycosis -- Toenail",
    "description": "Kerydin (tavaborole) is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails.",
    "middle_radius": 399,
    "inner_radius": 399
  },
  {
    "x": 2011.75,
    "y": 100,
    "r": 224,
    "category": 10,
    "company": "ApoPharma",
    "dates_clean": "2011-10-14",
    "brand_name": "Ferriprox",
    "condition": "Hemosiderosis",
    "description": "Ferriprox (deferiprone) is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2019.6667,
    "y": 100,
    "r": 1199,
    "category": 2,
    "company": "Ardelyx",
    "dates_clean": "2019-09-12",
    "brand_name": "Ibsrela",
    "condition": "Irritable Bowel Syndrome",
    "description": "Ibsrela (tenapanor) is a first-in-class, sodium/hydrogen exchanger 3 (NHE3) inhibitor indicated for the treatment of adults with irritable bowel syndrome with constipation (IBS-C).",
    "middle_radius": 599,
    "inner_radius": 599
  },
  {
    "x": 2012.4167,
    "y": 100,
    "r": 6635,
    "category": 2,
    "company": "Arena Pharmaceuticals",
    "dates_clean": "2012-06-27",
    "brand_name": "Belviq",
    "condition": "Obesity",
    "description": "Belviq (lorcaserin) is a serotonin 2C receptor agonist indicated for chronic weight management in adults who are obese, or overweight and who have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.",
    "middle_radius": 3286,
    "inner_radius": 3286
  },
  {
    "x": 2012.9167,
    "y": 100,
    "r": 444,
    "category": 7,
    "company": "Ariad Pharmaceuticals",
    "dates_clean": "2012-12-14",
    "brand_name": "Iclusig",
    "condition": "Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia",
    "description": "Iclusig (ponatinib) is a kinase inhibitor  for the treatment of chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2018.4167,
    "y": 100,
    "r": 577,
    "category": 7,
    "company": "Array BioPharma",
    "dates_clean": "2018-06-27",
    "brand_name": "Braftovi",
    "condition": "Melanoma -- Metastatic",
    "description": "Braftovi (encorafenib) is a kinase inhibitor indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.",
    "middle_radius": 191,
    "inner_radius": 0
  },
  {
    "x": 2018.4167,
    "y": 100,
    "r": 383,
    "category": 7,
    "company": "Array BioPharma",
    "dates_clean": "2018-06-27",
    "brand_name": "Mektovi",
    "condition": "Melanoma -- Metastatic",
    "description": "Mektovi (binimetinib)  is a kinase inhibitor indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.",
    "middle_radius": 191,
    "inner_radius": 0
  },
  {
    "x": 2015.1667,
    "y": 100,
    "r": 62,
    "category": 2,
    "company": "Asklepion Pharmaceuticals",
    "dates_clean": "2015-03-17",
    "brand_name": "Cholbam",
    "condition": "Bile Acid Synthesis Disorders",
    "description": "Cholbam (cholic acid) is a bile acid preparation for the treatment of patients with bile acid synthesis disorders due to single enzyme defects, and for patients with peroxisomal disorders (including Zellweger spectrum disorders).",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2019.9167,
    "y": 100,
    "r": 125,
    "category": 7,
    "company": "Astellas Pharma",
    "dates_clean": "2019-12-18",
    "brand_name": "Padcev",
    "condition": "Urothelial Carcinoma",
    "description": "Padcev (enfortumab vedotin-ejfv) is a Nectin-4 targeted antibody-drug conjugate (ADC) for the treatment of patients with locally advanced or metastatic urothelial cancer.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2018.8333,
    "y": 100,
    "r": 138,
    "category": 7,
    "company": "Astellas Pharma",
    "dates_clean": "2018-11-28",
    "brand_name": "Xospata",
    "condition": "Acute Myeloid Leukemia",
    "description": "Xospata (gilteritinib) is a FLT3/AXL kinase inhibitor indicated for the treatment of patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2012.5833,
    "y": 100,
    "r": 1199,
    "category": 7,
    "company": "Astellas Pharma",
    "dates_clean": "2012-08-31",
    "brand_name": "Xtandi",
    "condition": "Prostate Cancer",
    "description": "Xtandi (enzalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with castration-resistant prostate cancer, and metastatic castration-sensitive prostate cancer.",
    "middle_radius": 399,
    "inner_radius": 399
  },
  {
    "x": 2012.4167,
    "y": 100,
    "r": 2007,
    "category": 10,
    "company": "Astellas Pharma",
    "dates_clean": "2012-06-28",
    "brand_name": "Myrbetriq",
    "condition": "Overactive Bladder",
    "description": "Myrbetriq (mirabegron) is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.",
    "middle_radius": 878,
    "inner_radius": 878
  },
  {
    "x": 2015.1667,
    "y": 100,
    "r": 553,
    "category": 6,
    "company": "Astellas Pharma",
    "dates_clean": "2015-03-06",
    "brand_name": "Cresemba",
    "condition": "Invasive Aspergillosis; Invasive Mucormycosis",
    "description": "Cresemba (isavuconazonium) is an azole antifungal indicated for the treatment of invasive aspergillosis and invasive mucormycosis.",
    "middle_radius": 258,
    "inner_radius": 0
  },
  {
    "x": 2018.3333,
    "y": 100,
    "r": 1828,
    "category": 10,
    "company": "AstraZeneca",
    "dates_clean": "2018-05-18",
    "brand_name": "Lokelma",
    "condition": "Hyperkalemia",
    "description": "Lokelma (sodium zirconium cyclosilicate) is a potassium binder indicated for the treatment of hyperkalemia in adults.",
    "middle_radius": 240,
    "inner_radius": 240
  },
  {
    "x": 2017.8333,
    "y": 100,
    "r": 1805,
    "category": 9,
    "company": "AstraZeneca",
    "dates_clean": "2017-11-14",
    "brand_name": "Fasenra",
    "condition": "Asthma",
    "description": "Fasenra (benralizumab) is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody indicated for the treatment of patients with severe eosinophilic asthma.",
    "inner_radius": 760
  },
  {
    "x": 2017.75,
    "y": 100,
    "r": 124,
    "category": 7,
    "company": "AstraZeneca",
    "dates_clean": "2017-10-31",
    "brand_name": "Calquence",
    "condition": "Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia",
    "description": "Calquence (acalabrutinib) is a highly selective, potent, Bruton tyrosine kinase (BTK) inhibitor for the treatment of mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2017.3333,
    "y": 100,
    "r": 182,
    "category": 7,
    "company": "AstraZeneca",
    "dates_clean": "2017-05-01",
    "brand_name": "Imfinzi",
    "condition": "Urothelial Carcinoma, Non-Small Cell Lung Cancer",
    "description": "Imfinzi (durvalumab) is an anti-PD-L1 (programmed death ligand-1) human monoclonal antibody for the treatment of patients with metastatic urothelial carcinoma and for the treatment of patients with unresectable non-small cell lung cancer that has not progressed after chemoradiation.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2014.9167,
    "y": 100,
    "r": 137,
    "category": 7,
    "company": "AstraZeneca",
    "dates_clean": "2014-12-19",
    "brand_name": "Lynparza",
    "condition": "Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer",
    "description": "Lynparza capsules (discontinued) and tablets are indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2014,
    "y": 100,
    "r": 2876,
    "category": 2,
    "company": "AstraZeneca",
    "dates_clean": "2014-01-08",
    "brand_name": "Farxiga",
    "condition": "Diabetes Type 2",
    "description": "Farxiga (dapagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.",
    "middle_radius": 1032,
    "inner_radius": 1032
  },
  {
    "x": 2011.5,
    "y": 100,
    "r": 18624,
    "category": 3,
    "company": "AstraZeneca",
    "dates_clean": "2011-07-20",
    "brand_name": "Brilinta",
    "condition": "Acute Coronary Syndrome",
    "description": "Brilinta (ticagrelor) is a P2Y12 platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in  patients with acute coronary syndrome.",
    "middle_radius": 9291,
    "inner_radius": 0
  },
  {
    "x": 2011.25,
    "y": 100,
    "r": 331,
    "category": 7,
    "company": "AstraZeneca",
    "dates_clean": "2011-04-06",
    "brand_name": "Caprelsa",
    "condition": "Thyroid Cancer",
    "description": "Caprelsa (vandetanib) is a kinase inhibitor indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable (non-operable) locally advanced or metastatic disease.",
    "middle_radius": 100,
    "inner_radius": 0
  },
  {
    "x": 2019.9167,
    "y": 100,
    "r": 184,
    "category": 7,
    "company": "AstraZeneca and Daiichi Sankyo",
    "dates_clean": "2019-12-20",
    "brand_name": "enhertu",
    "condition": "Breast Cancer",
    "description": "Enhertu (fam-trastuzumab deruxtecan-nxki) is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2018.6667,
    "y": 100,
    "r": 80,
    "category": 7,
    "company": "AstraZeneca and MedImmune",
    "dates_clean": "2018-09-13",
    "brand_name": "Lumoxiti",
    "condition": "Hairy Cell Leukemia",
    "description": "Lumoxiti (moxetumomab pasudotox-tdfk) is an anti-CD22 recombinant immunotoxin for the treatment of adult patients with hairy cell leukemia.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2015.8333,
    "y": 100,
    "r": 411,
    "category": 7,
    "company": "AstraZeneca",
    "dates_clean": "2015-11-13",
    "brand_name": "Tagrisso",
    "condition": "Non-Small Cell Lung Cancer",
    "description": "Tagrisso (osimertinib) is a tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR) indicated for the treatment of patients with metastatic EGFR T790M mutation-positive non-small cell lung cancer.\r\r\r\r",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2014.6667,
    "y": 100,
    "r": 1337,
    "category": 2,
    "company": "AstraZeneca",
    "dates_clean": "2014-09-16",
    "brand_name": "Movantik",
    "condition": "Opioid-Induced Constipation",
    "description": "Movantik (naloxegol) is a peripherally-acting mu-opioid receptor antagonist indicated for the treatment of opioid-induced constipation.",
    "middle_radius": 446,
    "inner_radius": 446
  },
  {
    "x": 2019.9167,
    "y": 100,
    "r": 1614,
    "category": 5,
    "company": "Bausch Health Companies",
    "dates_clean": "2019-12-18",
    "brand_name": "Aralzo",
    "condition": "Acne",
    "description": "Arazlo (tazarotene) is a lotion formulation of the approved retinoid tazarotene for the topical treatment of acne vulgaris in patients 9 years of age and older.",
    "middle_radius": 815,
    "inner_radius": 815
  },
  {
    "x": 2013.4167,
    "y": 100,
    "r": 73,
    "category": 3,
    "company": "Baxter International",
    "dates_clean": "2013-06-26",
    "brand_name": "Rixubis",
    "condition": "Hemophilia B",
    "description": "Rixubis (coagulation factor IX, recombinant) is an antihemophilic factor indicated for the control and prevention of bleeding episodes in adults with hemophilia B.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2019.5,
    "y": 100,
    "r": 1509,
    "category": 7,
    "company": "Bayer",
    "dates_clean": "2019-07-30",
    "brand_name": "Nubeqa",
    "condition": "Prostate Cancer",
    "description": "Nubeqa (darolutamide) is an androgen receptor inhibitor (ARi) indicated for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC).",
    "middle_radius": 554,
    "inner_radius": 554
  },
  {
    "x": 2013.75,
    "y": 100,
    "r": 616,
    "category": 4,
    "company": "Bayer",
    "dates_clean": "2013-10-08",
    "brand_name": "Adempas",
    "condition": "Pulmonary Hypertension",
    "description": "Adempas (riociguat) is an oral soluble guanylate cyclase (sGC) stimulator for the treatment of pulmonary hypertension.",
    "middle_radius": 126,
    "inner_radius": 126
  },
  {
    "x": 2013.3333,
    "y": 100,
    "r": 921,
    "category": 7,
    "company": "Bayer",
    "dates_clean": "2013-05-15",
    "brand_name": "Xofigo",
    "condition": "Prostate Cancer",
    "description": "Xofigo (radium 223 dichloride) is an alpha particle-emitting radioactive therapeutic agent indicated for the treatment of patients with castration-resistant prostate cancer.",
    "middle_radius": 307,
    "inner_radius": 307
  },
  {
    "x": 2012.6667,
    "y": 100,
    "r": 760,
    "category": 7,
    "company": "Bayer",
    "dates_clean": "2012-09-27",
    "brand_name": "Stivarga",
    "condition": "Colorectal Cancer, Gastrointestinal Stromal Tumor, Hepatocellular Carcinoma",
    "description": "Stivarga (regorafenib) is an oral multi-kinase inhibitor for the treatment of patients with metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma.",
    "middle_radius": 255,
    "inner_radius": 255
  },
  {
    "x": 2010.3333,
    "y": 100,
    "r": 2665,
    "category": 10,
    "company": "Bayer",
    "dates_clean": "2010-05-06",
    "brand_name": "Natazia",
    "condition": "Contraception, Heavy Menstrual Bleeding",
    "description": "Natazia (dienogest and estradiol valerate) is a combination oral contraceptive indicated for use by women to prevent pregnancy and to treat heavy menstrual bleeding.",
    "middle_radius": 399,
    "inner_radius": 0
  },
  {
    "x": 2017.6667,
    "y": 100,
    "r": 104,
    "category": 7,
    "company": "Bayer",
    "dates_clean": "2017-09-14",
    "brand_name": "Aliqopa",
    "condition": "Follicular Lymphoma",
    "description": "Aliqopa (copanlisib) is a phosphatidylinositol-3-kinase (PI3K) inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL).",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2019.8333,
    "y": 100,
    "r": 118,
    "category": 7,
    "company": "BeiGene",
    "dates_clean": "2019-11-14",
    "brand_name": "Brukinsa",
    "condition": "Mantle Cell Lymphoma",
    "description": "Brukinsa (zanubrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2018.5833,
    "y": 100,
    "r": 64,
    "category": 1,
    "company": "Biocodex",
    "dates_clean": "2018-08-20",
    "brand_name": "Diacomit",
    "condition": "Dravet Syndrome",
    "description": "Diacomit (stiripentol) is an anticonvulsant indicated for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam.",
    "middle_radius": 31,
    "inner_radius": 31
  },
  {
    "x": 2014.9167,
    "y": 100,
    "r": 300,
    "category": 6,
    "company": "BioCryst Pharmaceuticals",
    "dates_clean": "2014-12-19",
    "brand_name": "Rapivab",
    "condition": "Influenza",
    "description": "Rapivab (peramivir) is an influenza virus neuraminidase inhibitor indicated for the treatment of acute uncomplicated influenza.",
    "middle_radius": 101,
    "inner_radius": 101
  },
  {
    "x": 2016.9167,
    "y": 100,
    "r": 82,
    "category": 8,
    "company": "Biogen",
    "dates_clean": "2016-12-23",
    "brand_name": "Spinraza",
    "condition": "Spinal Muscular Atrophy",
    "description": "Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in  pediatric and adult patients.\r\r",
    "middle_radius": 30,
    "inner_radius": 30
  },
  {
    "x": 2014.5833,
    "y": 100,
    "r": 1012,
    "category": 7,
    "company": "Biogen",
    "dates_clean": "2014-08-15",
    "brand_name": "Plegridy",
    "condition": "Multiple Sclerosis",
    "description": "Plegridy (peginterferon beta-1a) is a pegylated interferon beta indicated for the treatment of patients with relapsing forms of multiple sclerosis.",
    "middle_radius": 500,
    "inner_radius": 500
  },
  {
    "x": 2013.1667,
    "y": 100,
    "r": 1540,
    "category": 7,
    "company": "Biogen",
    "dates_clean": "2013-03-27",
    "brand_name": "Tecfidera",
    "condition": "Multiple Sclerosis",
    "description": "Tecfidera (dimethyl fumarate) is an oral Nrf2 pathway activator for the treatment of relapsing forms of multiple sclerosis.",
    "middle_radius": 771,
    "inner_radius": 771
  },
  {
    "x": 2018.3333,
    "y": 100,
    "r": 86,
    "category": 1,
    "company": "BioMarin Pharmaceutical",
    "dates_clean": "2018-05-24",
    "brand_name": "Palynziq",
    "condition": "Phenylketonuria",
    "description": "Palynziq (pegvaliase-pqpz) is a phenylalanine-metabolizing enzyme indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria.",
    "middle_radius": 28,
    "inner_radius": 28
  },
  {
    "x": 2017.25,
    "y": 100,
    "r": 24,
    "category": 2,
    "company": "BioMarin Pharmaceutical",
    "dates_clean": "2017-04-27",
    "brand_name": "Brineura",
    "condition": "CLN2 Disease",
    "description": "Brineura (cerliponase alfa) is an enzyme replacement therapy for the restoration of tripeptidyl peptidase-1 (TPP1) enzyme activity in patients with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), or TPP1 deficiency, a form of Batten disease.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2014.0833,
    "y": 100,
    "r": 176,
    "category": 2,
    "company": "BioMarin Pharmaceutical",
    "dates_clean": "2014-02-14",
    "brand_name": "Vimizim",
    "condition": "Mucopolysaccharidosis Type IVA",
    "description": "Vimizim (elosufase alfa) is an enzyme replacement therapy for patients with Mucopolysaccharidosis Type IVA (Morquio A syndrome).",
    "middle_radius": 59,
    "inner_radius": 59
  },
  {
    "x": 2010.0833,
    "y": 100,
    "r": 372,
    "category": 10,
    "company": "BioSpecifics Technologies Corp.",
    "dates_clean": "2010-02-03",
    "brand_name": "Xiaflex",
    "condition": "Dupuytren's Contracture",
    "description": "Xiaflex (collagenase clostridium histolyticum) is a collagenase product for the treatment of Dupuytren's contracture, a condition that affects the connective tissue that lies beneath the skin in the palm.",
    "middle_radius": 124,
    "inner_radius": 124
  },
  {
    "x": 2012.9167,
    "y": 100,
    "r": 170,
    "category": 2,
    "company": "Biotest Pharmaceuticals Corporation",
    "dates_clean": "2012-12-21",
    "brand_name": "Gattex",
    "condition": "Primary Immunodeficiency Syndrome",
    "description": "Gattex (teduglutide) is a recombinant analog of human glucagon-like peptide 2 for the treatment of short bowel syndrome in adults and pediatric patients one year of age and older.",
    "middle_radius": 59,
    "inner_radius": 59
  },
  {
    "x": 2014.5,
    "y": 100,
    "r": 4230,
    "category": 9,
    "company": "Boehringer Ingelheim",
    "dates_clean": "2014-07-31",
    "brand_name": "Striverdi Respimat",
    "condition": "Chronic Obstructive Pulmonary Disease",
    "description": "Striverdi Respimat (olodaterol) is a once-daily, long-acting beta-agonist (LABA) for the maintenance treatment of chronic obstructive pulmonary disease (COPD).",
    "middle_radius": 1779,
    "inner_radius": 1171
  },
  {
    "x": 2013.5,
    "y": 100,
    "r": 345,
    "category": 7,
    "company": "Boehringer Ingelheim",
    "dates_clean": "2013-07-12",
    "brand_name": "Gilotrif",
    "condition": "Non-Small Cell Lung Cancer",
    "description": "Gilotrif (afatinib) is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC).",
    "middle_radius": 115,
    "inner_radius": 0
  },
  {
    "x": 2011.3333,
    "y": 100,
    "r": 3551,
    "category": 2,
    "company": "Boehringer Ingelheim",
    "dates_clean": "2011-05-02",
    "brand_name": "Tradjenta",
    "condition": "Diabetes Type 2",
    "description": "Tradjenta (linagliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.",
    "middle_radius": 1382,
    "inner_radius": 621
  },
  {
    "x": 2015.75,
    "y": 100,
    "r": 90,
    "category": 10,
    "company": "Boehringer Ingelheim",
    "dates_clean": "2015-10-16",
    "brand_name": "Praxbind",
    "condition": "Reversal Agent for Pradaxa",
    "description": "Praxbind (idarucizumab) is a humanized monoclonal antibody fragment (Fab) indicated as a specific reversal agent for the anticoagulant effect of dabigatran (Pradaxa).",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2015.3333,
    "y": 100,
    "r": 0,
    "category": 9,
    "company": "Boehringer Ingelheim",
    "dates_clean": "2015-05-21",
    "brand_name": "Stiolto Respimat",
    "condition": "Chronic Obstructive Pulmonary Disease",
    "description": "Stiolto Respimat (olodaterol and tiotropium bromide) is a long-acting beta agonist (LABA) and long-acting muscarinic antagonist (LAMA) fixed-dose combination for the treatment of chronic obstructive pulmonary disease (COPD)."
  },
  {
    "x": 2014.75,
    "y": 100,
    "r": 1228,
    "category": 7,
    "company": "Boehringer Ingelheim",
    "dates_clean": "2014-10-15",
    "brand_name": "Ofev",
    "condition": "Idiopathic Pulmonary Fibrosis; Sclerosis-Associated Interstitial Lung Disease",
    "description": "Ofev (nintedanib) is a small molecule tyrosine kinase inhibitor (TKI) indicated for the treatment of idiopathic pulmonary fibrosis, and systemic sclerosis-associated interstitial lung disease (SSc-ILD).",
    "middle_radius": 506,
    "inner_radius": 506
  },
  {
    "x": 2014.5833,
    "y": 100,
    "r": 4800,
    "category": 2,
    "company": "Boehringer Ingelheim",
    "dates_clean": "2014-08-01",
    "brand_name": "Jardiance",
    "condition": "Diabetes Type 2",
    "description": "Jardiance (empagliflozin) is a sodium glucose co-transporter-2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, and to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.",
    "middle_radius": 1775,
    "inner_radius": 995
  },
  {
    "x": 2010.75,
    "y": 100,
    "r": 18113,
    "category": 3,
    "company": "Boehringer Ingelheim",
    "dates_clean": "2010-10-19",
    "brand_name": "Pradaxa",
    "condition": "Prevention of Thromboembolism in Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism",
    "description": "Pradaxa (dabigatran etexilate) is a direct thrombin inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation; and for the treatment and reduction of risk of deep vein thrombosis and pulmonary embolism.",
    "middle_radius": 6022,
    "inner_radius": 6022
  },
  {
    "x": 2011.1667,
    "y": 100,
    "r": 676,
    "category": 7,
    "company": "Bristol-Myers Squibb",
    "dates_clean": "2011-03-25",
    "brand_name": "Yervoy",
    "condition": "Melanoma -- Metastatic, Renal Cell Carcinoma, Colorectal Cancer",
    "description": "Yervoy (ipilimumab) is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for the treatment of melanoma. Yervoy is also used in combination with Opdivo (nivolumab) for the treatment of advanced renal cell carcinoma, and microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer.",
    "middle_radius": 136,
    "inner_radius": 0
  },
  {
    "x": 2015.5,
    "y": 100,
    "r": 152,
    "category": 6,
    "company": "Bristol-Myers Squibb",
    "dates_clean": "2015-07-24",
    "brand_name": "Daklinza",
    "condition": "Chronic Hepatitis C",
    "description": "Daklinza (daclatasvir) is an NS5A inhibitor indicated for use in combination with sofosbuvir for the treatment of chronic hepatitis C virus (HCV) genotype 1 or genotype 3 infection.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2014.9167,
    "y": 100,
    "r": 509,
    "category": 7,
    "company": "Bristol-Myers Squibb",
    "dates_clean": "2014-12-22",
    "brand_name": "Opdivo",
    "condition": "Melanoma -- Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Hodgkin's Disease, Head and Neck Cancer, Urothelial Carcinoma, Colorectal Cancer, Hepatocellular Carcinoma, Small Cell Lung Cancer",
    "description": "Opdivo (nivolumab) is a programmed death receptor-1 (PD-1) blocking antibody for the treatment of advanced melanoma, advanced non-small cell lung cancer, advanced small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, advanced squamous cell carcinoma of the head and neck, urothelial carcinoma, MSI-H or dMMR metastatic colorectal cancer, and hepatocellular carcinoma.",
    "middle_radius": 137,
    "inner_radius": 0
  },
  {
    "x": 2011.4167,
    "y": 100,
    "r": 1209,
    "category": 7,
    "company": "Bristol-Myers Squibb",
    "dates_clean": "2011-06-15",
    "brand_name": "Nulojix",
    "condition": "Organ Transplant -- Rejection Prophylaxis",
    "description": "Nulojix (belatacept) is a selective T-cell costimulation blocker indicated for prophylaxis of organ rejection in adult patients receiving a kidney transplant.",
    "middle_radius": 405,
    "inner_radius": 0
  },
  {
    "x": 2015.8333,
    "y": 100,
    "r": 646,
    "category": 7,
    "company": "Bristol-Myers Squibb",
    "dates_clean": "2015-11-30",
    "brand_name": "Empliciti",
    "condition": "Multiple Myeloma",
    "description": "Empliciti (elotuzumab) is a Signaling Lymphocyte Activation Molecule (SLAMF7)-directed immunostimulatory antibody indicated for the combination treatment of patients with multiple myeloma.",
    "middle_radius": 325,
    "inner_radius": 0
  },
  {
    "x": 2012,
    "y": 100,
    "r": 22,
    "category": 10,
    "company": "BTG International",
    "dates_clean": "2012-01-17",
    "brand_name": "Voraxaze",
    "condition": "Toxic Methotrexate Levels",
    "description": "Voraxaze (glucarpidase) is a carboxypeptidase enzyme indicated for the treatment of toxic plasma methotrexate levels in patients with delayed methotrexate clearance due to impaired renal function.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2012.9167,
    "y": 100,
    "r": 29,
    "category": 4,
    "company": "Cangene Corporation",
    "dates_clean": "2012-12-20",
    "brand_name": "Juxtapid",
    "condition": "Varicella-Zoster",
    "description": "Juxtapid (lomitapide) is a microsomal triglyceride transfer protein inhibitor indicated for the treatment of patients with homozygous familial hypercholesterolemia.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2018.8333,
    "y": 100,
    "r": 64,
    "category": 1,
    "company": "Catalyst Pharmaceuticals",
    "dates_clean": "2018-11-28",
    "brand_name": "Firdapse",
    "condition": "Lambert Eaton Myasthenic Syndrome",
    "description": "Firdapse (amifampridine phosphate) is a nonspecific, voltage-dependent, potassium (K+) channel blocker for the treatment of Lambert Eaton myasthenic syndrome (LEMS) in adults.",
    "middle_radius": 35,
    "inner_radius": 35
  },
  {
    "x": 2019.8333,
    "y": 100,
    "r": 336,
    "category": 3,
    "company": "Celgene Corporation",
    "dates_clean": "2019-11-08",
    "brand_name": "Reblozyl",
    "condition": "Beta-Thalassemia-Associated Anemia",
    "description": "Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation agent (EMA) for the treatment of transfusion-dependent beta-thalassemia-associated anemia.",
    "middle_radius": 112,
    "inner_radius": 112
  },
  {
    "x": 2019.5833,
    "y": 100,
    "r": 289,
    "category": 7,
    "company": "Celgene Corporation",
    "dates_clean": "2019-08-16",
    "brand_name": "Inrebic",
    "condition": "Myelofibrosis",
    "description": "Inrebic (fedratinib) is a highly selective JAK2 inhibitor for the treatment of patients with myelofibrosis.",
    "middle_radius": 96,
    "inner_radius": 96
  },
  {
    "x": 2017.5833,
    "y": 100,
    "r": 199,
    "category": 7,
    "company": "Celgene Corporation",
    "dates_clean": "2017-08-01",
    "brand_name": "Idhifa",
    "condition": "Acute Myeloid Leukemia",
    "description": "Idhifa (enasidenib) is a first-in-class, oral, targeted inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with an IDH2 mutation.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2014.1667,
    "y": 100,
    "r": 993,
    "category": 7,
    "company": "Celgene Corporation",
    "dates_clean": "2014-03-21",
    "brand_name": "Otezla",
    "condition": "Psoriatic Arthritis, Plaque Psoriasis, Behcet's Disease",
    "description": "Otezla (apremilast) is a phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of psoriatic arthritis, plaque psoriasis, and oral ulcers associated with Behí_etäó»s Disease.",
    "middle_radius": 496,
    "inner_radius": 496
  },
  {
    "x": 2013.0833,
    "y": 100,
    "r": 221,
    "category": 7,
    "company": "Celgene Corporation",
    "dates_clean": "2013-02-08",
    "brand_name": "Pomalyst",
    "condition": "Multiple Myeloma",
    "description": "Pomalyst (pomalidomide) is a thalidomide analogue indicated for the treatment of patients with multiple myeloma.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2011.25,
    "y": 100,
    "r": 1195,
    "category": 7,
    "company": "Centocor Ortho Biotech",
    "dates_clean": "2011-04-28",
    "brand_name": "Zytiga",
    "condition": "Prostate Cancer",
    "description": "Zytiga (abiraterone acetate) is a CYP17 inhibitor indicated for the treatment of patients with metastatic castration-resistant prostate cancer and metastatic high-risk castration-sensitive prostate cancer.",
    "middle_radius": 398,
    "inner_radius": 398
  },
  {
    "x": 2014.0833,
    "y": 100,
    "r": 338,
    "category": 4,
    "company": "Chelsea Therapeutics",
    "dates_clean": "2014-02-18",
    "brand_name": "Northera",
    "condition": "Neurogenic Orthostatic Hypotension",
    "description": "Northera (droxidopa) is an orally active synthetic precursor of norepinephrine indicated for the treatment of neurogenic orthostatic hypotension.",
    "middle_radius": 168,
    "inner_radius": 168
  },
  {
    "x": 2010.1667,
    "y": 100,
    "r": 158,
    "category": 4,
    "company": "Chemische Fabrik Kreussler",
    "dates_clean": "2010-03-30",
    "brand_name": "Asclera",
    "condition": "Varicose Vein",
    "description": "Asclera (polidocanol) is a sclerosing agent used for the treatment of varicose veins.",
    "middle_radius": 53,
    "inner_radius": 53
  },
  {
    "x": 2017.5833,
    "y": 100,
    "r": 545,
    "category": 6,
    "company": "Chemo Research",
    "dates_clean": "2017-08-29",
    "brand_name": "Vabomere",
    "condition": "Chagas Disease",
    "description": "Vabomere (meropenem and vaborbactam) is a carbapenem and beta-lactamase inhibitor combination for the treatment of complicated urinary tract infections (cUTIs).",
    "middle_radius": 273,
    "inner_radius": 0
  },
  {
    "x": 2019.75,
    "y": 100,
    "r": 167,
    "category": 5,
    "company": "Clinuvel Pharmaceuticals",
    "dates_clean": "2019-10-08",
    "brand_name": "Scenesse",
    "condition": "Prevention of Phototoxicity in Erythropoietic Protoporphyria",
    "description": "Scenesse (afamelanotide) is a selective agonist of the melanocortin 1 receptor (MC1R) indicated for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).",
    "middle_radius": 81,
    "inner_radius": 81
  },
  {
    "x": 2016.9167,
    "y": 100,
    "r": 106,
    "category": 7,
    "company": "Clovis Oncology",
    "dates_clean": "2016-12-19",
    "brand_name": "Rubraca",
    "condition": "Ovarian Cancer",
    "description": "Rubraca (rucaparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of patients with deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies; and for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2018.8333,
    "y": 100,
    "r": 264,
    "category": 10,
    "company": "Cosmo Technologies",
    "dates_clean": "2018-11-16",
    "brand_name": "Aemcolo",
    "condition": "Traveler's Diarrhea",
    "description": "Aemcolo (rifamycin) is a broad spectrum, orally non-absorbable antibiotic for the treatment of traveleräó»s diarrhea caused by noninvasive strains of Escherichia coli.",
    "middle_radius": 65,
    "inner_radius": 65
  },
  {
    "x": 2014.9167,
    "y": 100,
    "r": 1402,
    "category": 6,
    "company": "Cubist Pharmaceuticals",
    "dates_clean": "2014-12-19",
    "brand_name": "Zerbaxa",
    "condition": "Intraabdominal Infection, Urinary Tract Infection, Pneumonia",
    "description": "Zerbaxa (ceftolozane and tazobactam) is a cephalosporin and beta-lactamase inhibitor combination for the treatment of cIAIs and cUTIs caused by ESBL-producing Enterobacteriaceae species, drug-resistant P. aeruginosa, and some Streptococcus species.",
    "middle_radius": 738,
    "inner_radius": 0
  },
  {
    "x": 2014.4167,
    "y": 100,
    "r": 1315,
    "category": 6,
    "company": "Cubist Pharmaceuticals",
    "dates_clean": "2014-06-20",
    "brand_name": "Sivextro",
    "condition": "Skin and Structure Infection",
    "description": "Sivextro (tedizolid phosphate) is an oxazolidinone antibiotic drug indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI).",
    "middle_radius": 660,
    "inner_radius": 0
  },
  {
    "x": 2015,
    "y": 100,
    "r": 21026,
    "category": 3,
    "company": "Daiichi Sankyo Company",
    "dates_clean": "2015-01-08",
    "brand_name": "Savaysa",
    "condition": "Prevention of Thromboembolism in Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism",
    "description": "Savaysa (edoxaban) is an oral, once-daily factor Xa inhibitor anticoagulant indicated for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the treatment of deep vein thrombosis, and pulmonary embolism.",
    "middle_radius": 7012,
    "inner_radius": 0
  },
  {
    "x": 2019.5833,
    "y": 100,
    "r": 120,
    "category": 7,
    "company": "Daiichi Sankyo Company",
    "dates_clean": "2019-08-02",
    "brand_name": "Turalio",
    "condition": "Tenosynovial Giant Cell Tumor",
    "description": "Turalio (pexidartinib) is a kinase inhibitor indicated for the treatment of symptomatic tenosynovial giant cell tumor (TGCT) in adults.",
    "middle_radius": 59,
    "inner_radius": 59
  },
  {
    "x": 2010.75,
    "y": 100,
    "r": 1260,
    "category": 1,
    "company": "Dainippon Sumitomo",
    "dates_clean": "2010-10-28",
    "brand_name": "Latuda",
    "condition": "Schizophrenia, Bipolar Disorder",
    "description": "Latuda (lurasidone) is an atypical antipsychotic agent for the treatment of schizophrenia and bipolar depression.",
    "middle_radius": 385,
    "inner_radius": 385
  },
  {
    "x": 2012.1667,
    "y": 100,
    "r": 1294,
    "category": 9,
    "company": "Discovery Laboratories",
    "dates_clean": "2012-03-06",
    "brand_name": "Surfaxin",
    "condition": "Respiratory Distress Syndrome",
    "description": "Surfaxin (lucinactant) is a synthetic, peptide-containing surfactant indicated for the prevention of respiratory distress syndrome (RDS) in premature infants.",
    "middle_radius": 767,
    "inner_radius": 0
  },
  {
    "x": 2018.5833,
    "y": 100,
    "r": 148,
    "category": 10,
    "company": "Dompí© farmaceutici SpA",
    "dates_clean": "2018-08-22",
    "brand_name": "Oxervate",
    "condition": "Neurotrophic Keratitis",
    "description": "Oxervate (cenegermin) is a recombinant human nerve growth factor (rhNGF) ophthalmic solution indicated for the treatment of neurotrophic keratitis.",
    "middle_radius": 75,
    "inner_radius": 75
  },
  {
    "x": 2018.3333,
    "y": 100,
    "r": 435,
    "category": 3,
    "company": "Dova Pharmaceuticals",
    "dates_clean": "2018-05-21",
    "brand_name": "Doptelet",
    "condition": "Thrombocytopenia, Idiopathic (Immune) Thrombocytopenic Purpura",
    "description": "Doptelet (avatrombopag) is a second generation, orally administered thrombopoietin receptor agonist (TPO-RA) indicated for the treatment of Thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.",
    "middle_radius": 158,
    "inner_radius": 158
  },
  {
    "x": 2013.0833,
    "y": 100,
    "r": 2180,
    "category": 10,
    "company": "Duchesnay",
    "dates_clean": "2013-02-26",
    "brand_name": "Osphena",
    "condition": "Dyspareunia, Atrophic Vaginitis",
    "description": "Osphena (ospemifene) is an estrogen agonist/antagonist indicated for the treatment of symptoms of vulvar and vaginal atrophy due to menopause, including severe dyspareunia and moderate to severe vaginal dryness.",
    "middle_radius": 796,
    "inner_radius": 796
  },
  {
    "x": 2019.9167,
    "y": 100,
    "r": 1714,
    "category": 1,
    "company": "Eisai",
    "dates_clean": "2019-12-20",
    "brand_name": "dayvigo",
    "condition": "Insomnia",
    "description": "Dayvigo (lemborexant) is dual orexin receptor antagonist (DORA) for the treatment of insomnia.",
    "middle_radius": 533,
    "inner_radius": 533
  },
  {
    "x": 2015.0833,
    "y": 100,
    "r": 392,
    "category": 7,
    "company": "Eisai",
    "dates_clean": "2015-02-13",
    "brand_name": "Lenvima",
    "condition": "Thyroid Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma, Endometrial Carcinoma",
    "description": "Lenvima (lenvatinib) is a multiple receptor tyrosine kinase (RTK) inhibitor for the treatment of  thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma.",
    "middle_radius": 131,
    "inner_radius": 131
  },
  {
    "x": 2012.75,
    "y": 100,
    "r": 1480,
    "category": 1,
    "company": "Eisai",
    "dates_clean": "2012-10-22",
    "brand_name": "Fycompa",
    "condition": "Epilepsy, Seizures",
    "description": "Fycompa (perampanel) is a non-competitive AMPA glutamate receptor antagonist indicated for the treatment of partial-onset seizures, and as adjunctive therapy in the treatment of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy.",
    "middle_radius": 442,
    "inner_radius": 442
  },
  {
    "x": 2019.75,
    "y": 100,
    "r": 4439,
    "category": 1,
    "company": "Eli Lilly and Company",
    "dates_clean": "2019-10-11",
    "brand_name": "Reyvow",
    "condition": "Migraine",
    "description": "Reyvow (lasmiditan) is a serotonin (5-HT)1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults.",
    "middle_radius": 1262,
    "inner_radius": 1262
  },
  {
    "x": 2018.6667,
    "y": 100,
    "r": 2831,
    "category": 1,
    "company": "Eli Lilly and Company",
    "dates_clean": "2018-09-27",
    "brand_name": "Emgality",
    "condition": "Migraine Prophylaxis, Cluster Headache",
    "description": "Emgality (galcanezumab-gnlm) is a calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of migraine, and for the treatment of episodic cluster headache.",
    "middle_radius": 1413,
    "inner_radius": 1413
  },
  {
    "x": 2017.6667,
    "y": 100,
    "r": 801,
    "category": 7,
    "company": "Eli Lilly and Company",
    "dates_clean": "2017-09-28",
    "brand_name": "Verzenio",
    "condition": "Breast Cancer",
    "description": "Verzenio (abemaciclib) is a selective ATP-competitive inhibitor of cyclin dependent kinases (CDK) 4 and 6 indicated for the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer.\r\r",
    "middle_radius": 223,
    "inner_radius": 223
  },
  {
    "x": 2016.75,
    "y": 100,
    "r": 133,
    "category": 7,
    "company": "Eli Lilly and Company",
    "dates_clean": "2016-10-19",
    "brand_name": "Lartruvo",
    "condition": "Soft Tissue Sarcoma",
    "description": "Lartruvo (olaratumab) is a platelet-derived growth factor receptor alpha (PDGFR-‘±) blocking antibody indicated in combination with doxorubicin for the treatment of patients with advanced soft tissue sarcoma (STS).",
    "middle_radius": 67,
    "inner_radius": 0
  },
  {
    "x": 2016.1667,
    "y": 100,
    "r": 1961,
    "category": 7,
    "company": "Eli Lilly and Company",
    "dates_clean": "2016-03-22",
    "brand_name": "Taltz",
    "condition": "Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis",
    "description": "Taltz (ixekizumab) is a humanized interleukin-17A antagonist indicated for the treatment of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.",
    "middle_radius": 792,
    "inner_radius": 792
  },
  {
    "x": 2015.8333,
    "y": 100,
    "r": 1726,
    "category": 7,
    "company": "Eli Lilly and Company",
    "dates_clean": "2015-11-24",
    "brand_name": "Portrazza",
    "condition": "Non-Small Cell Lung Cancer",
    "description": "Portrazza (necitumumab) is an epidermal growth factor receptor (EGFR) antagonist indicated in combination with gemcitabine and cisplatin for the treatment of patients with metastatic squamous non-small cell lung cancer.",
    "middle_radius": 866,
    "inner_radius": 0
  },
  {
    "x": 2014.6667,
    "y": 100,
    "r": 4446,
    "category": 2,
    "company": "Eli Lilly and Company",
    "dates_clean": "2014-09-18",
    "brand_name": "Trulicity",
    "condition": "Diabetes Type 2",
    "description": "Trulicity (dulaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes.",
    "middle_radius": 1655,
    "inner_radius": 280
  },
  {
    "x": 2014.25,
    "y": 100,
    "r": 355,
    "category": 7,
    "company": "Eli Lilly and Company",
    "dates_clean": "2014-04-21",
    "brand_name": "Cyramza",
    "condition": "Gastric Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Hepatocellular Carcinoma",
    "description": "Cyramza (ramucirumab) is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated for advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single-agent after prior fluoropyrimidine- or platinum-containing chemotherapy.",
    "middle_radius": 117,
    "inner_radius": 117
  },
  {
    "x": 2018.3333,
    "y": 100,
    "r": 807,
    "category": 7,
    "company": "Eli Lilly and Company",
    "dates_clean": "2018-05-31",
    "brand_name": "Olumiant",
    "condition": "Rheumatoid Arthritis",
    "description": "Olumiant (baricitinib) is a Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.",
    "middle_radius": 404,
    "inner_radius": 404
  },
  {
    "x": 2016.1667,
    "y": 100,
    "r": 0,
    "category": 6,
    "company": "Elusys Therapeutics",
    "dates_clean": "2016-03-18",
    "brand_name": "Anthim",
    "condition": "Anthrax Prophylaxis, Inhalation Bacillus anthracis",
    "description": "Anthim (obiltoxaximab) is a monoclonal antibody (mAb) anthrax antitoxin for the treatment and prevention of inhalational anthrax.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2017.1667,
    "y": 100,
    "r": 88,
    "category": 7,
    "company": "EMD Serono",
    "dates_clean": "2017-03-23",
    "brand_name": "Bavencio",
    "condition": "Merkel Cell Carcinoma, Urothelial Carcinoma, Renal Cell Carcinoma",
    "description": "Bavencio (avelumab) is a programmed death ligand-1 (PD-L1) blocking antibody indicated for the treatment of patients with metastatic Merkel cell carcinoma (MCC); patients with advanced or metastatic urothelial carcinoma; and in combination with axitinib for patients with advanced renal cell carcinoma.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2019.0833,
    "y": 100,
    "r": 654,
    "category": 5,
    "company": "Evolus",
    "dates_clean": "2019-02-01",
    "brand_name": "Jeuveau",
    "condition": "Glabellar Lines",
    "description": "Jeuveau (prabotulinumtoxinA) is a proprietary 900 kDa purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar (frown) lines.",
    "middle_radius": 162,
    "inner_radius": 162
  },
  {
    "x": 2012.8333,
    "y": 100,
    "r": 330,
    "category": 7,
    "company": "Exelixis",
    "dates_clean": "2012-11-29",
    "brand_name": "Cometriq",
    "condition": "Thyroid Cancer",
    "description": "Cometriq (cabozantinib) is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.",
    "middle_radius": 111,
    "inner_radius": 111
  },
  {
    "x": 2012.5,
    "y": 100,
    "r": 1195,
    "category": 2,
    "company": "Ferring Pharmaceuticals",
    "dates_clean": "2012-07-16",
    "brand_name": "Prepopik",
    "condition": "Bowel Preparation",
    "description": "Prepopik (sodium picosulfate, magnesium oxide and citric acid) is a stimulant laxative and osmotic laxative combination indicated for cleansing of the colon as a preparation for colonoscopy in adults.",
    "middle_radius": 597,
    "inner_radius": 0
  },
  {
    "x": 2019.75,
    "y": 100,
    "r": 2420,
    "category": 5,
    "company": "Galderma",
    "dates_clean": "2019-10-04",
    "brand_name": "Aklief",
    "condition": "Acne",
    "description": "Aklief (trifarotene) is a topical retinoid indicated for the treatment of acne vulgaris in patients 9 years of age and older.",
    "middle_radius": 1206,
    "inner_radius": 1206
  },
  {
    "x": 2013.8333,
    "y": 100,
    "r": 356,
    "category": 7,
    "company": "Genentech",
    "dates_clean": "2013-11-01",
    "brand_name": "Gazyva",
    "condition": "Chronic Lymphocytic Leukemia, Follicular Lymphoma",
    "description": "Gazyva (obinutuzumab) is a CD20-directed cytolytic antibody indicated for the combination treatment of patients with chronic lymphocytic leukemia and follicular lymphoma.",
    "middle_radius": 118,
    "inner_radius": 0
  },
  {
    "x": 2012.4167,
    "y": 100,
    "r": 808,
    "category": 7,
    "company": "Genentech",
    "dates_clean": "2012-06-08",
    "brand_name": "Perjeta",
    "condition": "Breast Cancer",
    "description": "Perjeta (pertuzumab) is a humanized monoclonal antibody indicated for the treatment of HER2-positive breast cancer.",
    "middle_radius": 406,
    "inner_radius": 406
  },
  {
    "x": 2012,
    "y": 100,
    "r": 104,
    "category": 7,
    "company": "Genentech",
    "dates_clean": "2012-01-30",
    "brand_name": "Erivedge",
    "condition": "Basal Cell Carcinoma",
    "description": "Erivedge (vismodegib) is a hedgehog pathway inhibitor for the treatment of patients with advanced basal cell carcinoma (BCC).",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2010,
    "y": 100,
    "r": 4087,
    "category": 7,
    "company": "Genentech",
    "dates_clean": "2010-01-08",
    "brand_name": "Actemra",
    "condition": "Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Giant Cell Arteritis",
    "description": "Actemra (tocilizumab) is a humanized interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody for the treatment rheumatoid arthritis; systemic juvenile idiopathic arthritis (SJIA); polyarticular juvenile idiopathic arthritis (PJIA); giant cell arteritis; and CAR T cell-induced severe or life-threatening cytokine release syndrome.",
    "middle_radius": 1452,
    "inner_radius": 1168
  },
  {
    "x": 2019.5833,
    "y": 100,
    "r": 54,
    "category": 7,
    "company": "Genentech",
    "dates_clean": "2019-08-15",
    "brand_name": "Rozlytrek",
    "condition": "Solid Tumors, Non-Small Cell Lung Cancer",
    "description": "Rozlytrek (entrectinib) is a selective tyrosine kinase inhibitor for the treatment of patients with ROS1-positive, metastatic non-small cell lung cancer and neurotrophic tyrosine receptor kinase (NTRK) gene fusion-positive solid tumors.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2019.4167,
    "y": 100,
    "r": 80,
    "category": 7,
    "company": "Genentech",
    "dates_clean": "2019-06-10",
    "brand_name": "Polivy",
    "condition": "Diffuse Large B-Cell Lymphoma",
    "description": "Polivy (polatuzumab vedotin-piiq) is a CD79b-directed antibody drug conjugate indicated in combination with bendamustine and rituximab for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, who have received at least two prior therapies.",
    "middle_radius": 40,
    "inner_radius": 0
  },
  {
    "x": 2018.75,
    "y": 100,
    "r": 885,
    "category": 6,
    "company": "Genentech",
    "dates_clean": "2018-10-24",
    "brand_name": "Xofluza",
    "condition": "Influenza",
    "description": "Xofluza (baloxavir marboxil) is a polymerase acidic (PA) endonuclease inhibitor for the treatment of influenza (the flu) in people 12 years of age and older who have had flu symptoms for no more than 48 hours and who are otherwise healthy, or at high risk of developing flu-related complications.",
    "middle_radius": 330,
    "inner_radius": 330
  },
  {
    "x": 2017.8333,
    "y": 100,
    "r": 176,
    "category": 3,
    "company": "Genentech",
    "dates_clean": "2017-11-16",
    "brand_name": "Hemlibra",
    "condition": "Hemophilia A with Inhibitors, Hemophilia A",
    "description": "Hemlibra (emicizumab-kxwh) is a bispecific factor IXa- and factor X-directed antibody indicated to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.",
    "middle_radius": 56,
    "inner_radius": 0
  },
  {
    "x": 2017.1667,
    "y": 100,
    "r": 1656,
    "category": 7,
    "company": "Genentech",
    "dates_clean": "2017-03-28",
    "brand_name": "Ocrevus",
    "condition": "Multiple Sclerosis",
    "description": "Ocrevus (ocrelizumab) is a humanized monoclonal antibody designed to selectively target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin and axonal nerve cell damage. Ocrevus is indicated as a treatment for both relapsing (RMS) and primary progressive (PPMS) forms of multiple sclerosis.",
    "middle_radius": 829,
    "inner_radius": 0
  },
  {
    "x": 2016.3333,
    "y": 100,
    "r": 310,
    "category": 7,
    "company": "Genentech",
    "dates_clean": "2016-05-18",
    "brand_name": "Tecentriq",
    "condition": "Bladder Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Small Cell Lung Cancer",
    "description": "Tecentriq (atezolizumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for use in the treatment of urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), and small cell lung cancer (SCLC).",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2015.9167,
    "y": 100,
    "r": 225,
    "category": 7,
    "company": "Genentech",
    "dates_clean": "2015-12-11",
    "brand_name": "Alecensa",
    "condition": "Non-Small Cell Lung Cancer",
    "description": "Alecensa (alectinib) is an oral, anaplastic lymphoma kinase (ALK) inhibitor for the treatment of ALK-positive non-small cell lung cancer (NSCLC).",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2015.8333,
    "y": 100,
    "r": 495,
    "category": 7,
    "company": "Genentech",
    "dates_clean": "2015-11-10",
    "brand_name": "Cotellic",
    "condition": "Melanoma -- Metastatic",
    "description": "Cotellic (cobimetinib) is a kinase inhibitor indicated for use in combination with vemurafenib for the treatment of advanced melanoma with a BRAF V600E or V600K mutation.",
    "middle_radius": 248,
    "inner_radius": 248
  },
  {
    "x": 2013.0833,
    "y": 100,
    "r": 991,
    "category": 7,
    "company": "Genentech",
    "dates_clean": "2013-02-22",
    "brand_name": "Kadcyla",
    "condition": "Breast Cancer",
    "description": "Kadcyla (ado-trastuzumab emtansine) is a HER2-targeted antibody and microtubule inhibitor conjugate indicated for the treatment of patients with HER2-positive, metastatic breast cancer.",
    "middle_radius": 496,
    "inner_radius": 0
  },
  {
    "x": 2011.5833,
    "y": 100,
    "r": 807,
    "category": 7,
    "company": "Genentech",
    "dates_clean": "2011-08-17",
    "brand_name": "Zelboraf",
    "condition": "Melanoma -- Metastatic",
    "description": "Zelboraf (vemurafenib) is a kinase inhibitor indicated for the treatment of patients with metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test, and for the treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation.",
    "middle_radius": 338,
    "inner_radius": 0
  },
  {
    "x": 2014.5833,
    "y": 100,
    "r": 186,
    "category": 2,
    "company": "Genzyme Corporation",
    "dates_clean": "2014-08-19",
    "brand_name": "Cerdelga",
    "condition": "Gaucher Disease",
    "description": "Cerdelga (eliglustat) is a glucosylceramide synthase inhibitor indicated for the long-term treatment of adult patients with Gaucher disease type 1.",
    "middle_radius": 67,
    "inner_radius": 67
  },
  {
    "x": 2010.3333,
    "y": 100,
    "r": 90,
    "category": 2,
    "company": "Genzyme Corporation",
    "dates_clean": "2010-05-24",
    "brand_name": "Lumizyme",
    "condition": "Pompe disease",
    "description": "Lumizyme (alglucosidase alfa) is a lysosomal glycogen-specific enzyme indicated for patients with Pompe disease.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2013.9167,
    "y": 100,
    "r": 1781,
    "category": 6,
    "company": "Gilead Sciences",
    "dates_clean": "2013-12-06",
    "brand_name": "Sovaldi",
    "condition": "Chronic Hepatitis C",
    "description": "Sovaldi (sofosbuvir) is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor indicated for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen.",
    "middle_radius": 314,
    "inner_radius": 71
  },
  {
    "x": 2018.0833,
    "y": 100,
    "r": 2414,
    "category": 6,
    "company": "Gilead Sciences",
    "dates_clean": "2018-02-07",
    "brand_name": "Biktarvy",
    "condition": "HIV Infection",
    "description": "Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide) is an integrase strand transfer inhibitor and emtricitabine/tenofovir alafenamide (Descovy) combination for the treatment of HIV-1 infection in adults.",
    "middle_radius": 1208,
    "inner_radius": 0
  },
  {
    "x": 2017.5,
    "y": 100,
    "r": 749,
    "category": 6,
    "company": "Gilead Sciences",
    "dates_clean": "2017-07-18",
    "brand_name": "Vosevi",
    "condition": "Chronic Hepatitis C",
    "description": "Vosevi (sofosbuvir, velpatasvir and voxilaprevir or SOF/VEL/VOX) is a fixed-dose combination of a nucleotide analog NS5B polymerase inhibitor (SOF), a pangenotypic NS5A inhibitor (VEL), and a pangenotypic NS3/4A protease inhibitor (VOX) for the treatment of genotype 1-6 chronic hepatitis C virus (HCV) infection.",
    "middle_radius": 152,
    "inner_radius": 152
  },
  {
    "x": 2016.4167,
    "y": 100,
    "r": 1825,
    "category": 6,
    "company": "Gilead Sciences",
    "dates_clean": "2016-06-28",
    "brand_name": "Epclusa",
    "condition": "Chronic Hepatitis C",
    "description": "Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A inhibitor fixed-dose combination for the treatment of chronic genotype 1-6 hepatitis C virus (HCV) infection.",
    "middle_radius": 523,
    "inner_radius": 116
  },
  {
    "x": 2015.8333,
    "y": 100,
    "r": 3194,
    "category": 6,
    "company": "Gilead Sciences",
    "dates_clean": "2015-11-05",
    "brand_name": "Genvoya",
    "condition": "HIV Infection",
    "description": "Genvoya (elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide or E/C/F/TAF) is an antiretroviral combination for the treatment of HIV infection.",
    "middle_radius": 1264,
    "inner_radius": 0
  },
  {
    "x": 2014.75,
    "y": 100,
    "r": 863,
    "category": 6,
    "company": "Gilead Sciences",
    "dates_clean": "2014-10-10",
    "brand_name": "Harvoni",
    "condition": "Chronic Hepatitis C",
    "description": "Harvoni (ledipasvir and sofosbuvir) is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, indicated for the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2014.5,
    "y": 100,
    "r": 318,
    "category": 7,
    "company": "Gilead Sciences",
    "dates_clean": "2014-07-23",
    "brand_name": "Zydelig",
    "condition": "non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma",
    "description": "Zydelig (idelalisib) is a phosphoinositide 3-kinase (PI3K) delta inhibitor for the treatment of chronic lymphocytic leukemia, relapsed follicular B-cell non-Hodgkin lymphoma, and relapsed small lymphocytic lymphoma.",
    "middle_radius": 110,
    "inner_radius": 110
  },
  {
    "x": 2012.5833,
    "y": 100,
    "r": 1408,
    "category": 10,
    "company": "Gilead Sciences",
    "dates_clean": "2012-08-27",
    "brand_name": "Stribild",
    "condition": "HIV Infection",
    "description": "Stribild (cobicistat, elvitegravir, emtricitabine and tenofovir) is a complete once-daily single tablet regimen for HIV-1 infection for treatment-naí¿ve adults.",
    "middle_radius": 707,
    "inner_radius": 0
  },
  {
    "x": 2018.5,
    "y": 100,
    "r": 371,
    "category": 10,
    "company": "GlaxoSmithKline",
    "dates_clean": "2018-07-20",
    "brand_name": "Krintafel",
    "condition": "Malaria",
    "description": "Krintafel (tafenoquine) is an 8-aminoquinoline derivative antimalarial for the radical cure (prevention of relapse) of Plasmodium vivax malaria.",
    "middle_radius": 54,
    "inner_radius": 54
  },
  {
    "x": 2013.3333,
    "y": 100,
    "r": 389,
    "category": 7,
    "company": "GlaxoSmithKline",
    "dates_clean": "2013-05-29",
    "brand_name": "Tafinlar",
    "condition": "Melanoma -- Metastatic, Non-Small Cell Lung Cancer, Thyroid Cancer",
    "description": "Tafinlar (dabrafenib) is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.",
    "middle_radius": 63,
    "inner_radius": 0
  },
  {
    "x": 2013.3333,
    "y": 100,
    "r": 322,
    "category": 7,
    "company": "GlaxoSmithKline",
    "dates_clean": "2013-05-29",
    "brand_name": "Mekinist",
    "condition": "Melanoma -- Metastatic, Non-Small Cell Lung Cancer, Thyroid Cancer",
    "description": "Mekinist (trametinib) is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.",
    "middle_radius": 108,
    "inner_radius": 0
  },
  {
    "x": 2012.9167,
    "y": 100,
    "r": 162,
    "category": 10,
    "company": "GlaxoSmithKline",
    "dates_clean": "2012-12-14",
    "brand_name": "Signifor",
    "condition": "Inhalation Bacillus anthracis",
    "description": "Signifor (pasireotide) is a multireceptor targeting somatostatin analog for the treatment of patients with Cushing's disease.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2014.25,
    "y": 100,
    "r": 4840,
    "category": 2,
    "company": "GlaxoSmithKline",
    "dates_clean": "2014-04-15",
    "brand_name": "Tanzeum",
    "condition": "Diabetes Type 2",
    "description": "Tanzeum (albiglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes.",
    "middle_radius": 2501,
    "inner_radius": 463
  },
  {
    "x": 2011.4167,
    "y": 100,
    "r": 1239,
    "category": 1,
    "company": "GlaxoSmithKline and Valeant",
    "dates_clean": "2011-06-10",
    "brand_name": "Potiga",
    "condition": "Seizures",
    "description": "Potiga (ezogabine) is a potassium channel opener indicated for the adjunctive treatment of adults with partial-onset seizures.",
    "middle_radius": 422,
    "inner_radius": 0
  },
  {
    "x": 2011.25,
    "y": 100,
    "r": 541,
    "category": 1,
    "company": "GlaxoSmithKline and XenoPort",
    "dates_clean": "2011-04-06",
    "brand_name": "Horizant",
    "condition": "Restless Legs Syndrome, Postherpetic Neuralgia",
    "description": "Horizant (gabapentin enacarbil) is a  gabapentin prodrug indicated for the once-daily treatment of restless legs syndrome and postherpetic neuralgia.",
    "middle_radius": 204,
    "inner_radius": 204
  },
  {
    "x": 2015.8333,
    "y": 100,
    "r": 711,
    "category": 9,
    "company": "GlaxoSmithKline",
    "dates_clean": "2015-11-04",
    "brand_name": "Nucala",
    "condition": "Asthma, Churg-Strauss Allergic Angiitis",
    "description": "Nucala (mepolizumab) is an interleukin-5 antagonist monoclonal antibody (IgG1 kappa) indicated for the add-on maintenance treatment of patients with severe eosinophilic asthma, and for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).",
    "middle_radius": 448,
    "inner_radius": 257
  },
  {
    "x": 2013.9167,
    "y": 100,
    "r": 5748,
    "category": 9,
    "company": "GlaxoSmithKline and Theravance",
    "dates_clean": "2013-12-18",
    "brand_name": "Anoro Ellipta",
    "condition": "Chronic Obstructive Pulmonary Disease",
    "description": "Anoro Ellipta (umeclidinium bromide and vilanterol) is a long-acting muscarinic antagonist (LAMA) and long-acting beta2 agonist (LABA) combination for the treatment of COPD.",
    "middle_radius": 1299,
    "inner_radius": 876
  },
  {
    "x": 2013.3333,
    "y": 100,
    "r": 5106,
    "category": 10,
    "company": "GlaxoSmithKline and Theravance",
    "dates_clean": "2013-05-10",
    "brand_name": "Breo Ellipta",
    "condition": "Chronic Obstructive Pulmonary Disease, Asthma",
    "description": "Breo Ellipta (fluticasone and vilanterol) is a once-a-day inhaled corticosteroid/long-acting beta2 agonist (LABA) combination indicated for the treatment of patients with chronic obstructive pulmonary disease (COPD) and asthma.",
    "middle_radius": 4312,
    "inner_radius": 395
  },
  {
    "x": 2019.8333,
    "y": 100,
    "r": 182,
    "category": 3,
    "company": "Global Blood Therapeutics",
    "dates_clean": "2019-11-25",
    "brand_name": "Oxbryta",
    "condition": "Sickle Cell Anemia",
    "description": "Oxbryta (voxelotor) is an oral, HbS (sickle hemoglobin) polymerization inhibitor for the treatment of patients with sickle cell disease (SCD).",
    "middle_radius": 91,
    "inner_radius": 91
  },
  {
    "x": 2018.4167,
    "y": 100,
    "r": 396,
    "category": 1,
    "company": "GW Pharmaceuticals",
    "dates_clean": "2018-06-25",
    "brand_name": "Epidiolex",
    "condition": "Lennox-Gastaut Syndrome, Dravet Syndrome",
    "description": "Epidiolex (cannabidiol) is a prescription pharmaceutical formulation of highly-purified, marijuana plant-derived cannabidiol (CBD) for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients two years of age or older.",
    "middle_radius": 161,
    "inner_radius": 161
  },
  {
    "x": 2019.5833,
    "y": 100,
    "r": 159,
    "category": 1,
    "company": "Harmony Biosciences",
    "dates_clean": "2019-08-14",
    "brand_name": "Wakix",
    "condition": "Narcolepsy",
    "description": "Wakix (pitolisant) is a histamine-3 (Hä‰€) receptor antagonist/inverse agonist for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy.",
    "middle_radius": 62,
    "inner_radius": 62
  },
  {
    "x": 2014.75,
    "y": 100,
    "r": 2030,
    "category": 2,
    "company": "Helsinn Group",
    "dates_clean": "2014-10-10",
    "brand_name": "Akynzeo",
    "condition": "Nausea/Vomiting -- Chemotherapy Induced",
    "description": "Akynzeo (netupitant and palonosetron) is a substance P/neurokinin 1 (NK1) receptor antagonist and serotonin-3 (5-HT3) receptor antagonist fixed-dose combination indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV).",
    "middle_radius": 861,
    "inner_radius": 0
  },
  {
    "x": 2010.5833,
    "y": 100,
    "r": 2930,
    "category": 10,
    "company": "HRA Pharma",
    "dates_clean": "2010-08-13",
    "brand_name": "ella",
    "condition": "Postcoital Contraception",
    "description": "ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure.",
    "middle_radius": 844,
    "inner_radius": 0
  },
  {
    "x": 2011.1667,
    "y": 100,
    "r": 1684,
    "category": 7,
    "company": "Human Genome Sciences and GlaxoSmithKline",
    "dates_clean": "2011-03-10",
    "brand_name": "Benlysta",
    "condition": "Systemic Lupus Erythematosus",
    "description": "Benlysta (belimumab) is B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of patients with systemic lupus erythematosus.",
    "middle_radius": 562,
    "inner_radius": 562
  },
  {
    "x": 2011.8333,
    "y": 100,
    "r": 528,
    "category": 7,
    "company": "Incyte Corporation",
    "dates_clean": "2011-11-16",
    "brand_name": "Jakafi",
    "condition": "Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease",
    "description": "Jakafi (ruxolitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of myelofibrosis.",
    "middle_radius": 227,
    "inner_radius": 154
  },
  {
    "x": 2016.3333,
    "y": 100,
    "r": 216,
    "category": 2,
    "company": "Intercept Pharmaceuticals",
    "dates_clean": "2016-05-27",
    "brand_name": "Ocaliva",
    "condition": "Biliary Cirrhosis",
    "description": "Ocaliva (obeticholic acid) is a first-in-class farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis.\r\r\r\r",
    "middle_radius": 73,
    "inner_radius": 73
  },
  {
    "x": 2014.75,
    "y": 100,
    "r": 1334,
    "category": 7,
    "company": "InterMune",
    "dates_clean": "2014-10-15",
    "brand_name": "Esbriet",
    "condition": "Idiopathic Pulmonary Fibrosis",
    "description": "Esbriet (pirfenidone) is a TGF-beta synthesis inhibitor for the treatment of patients with idiopathic pulmonary fibrosis (IPF).",
    "middle_radius": 624,
    "inner_radius": 624
  },
  {
    "x": 2019.9167,
    "y": 100,
    "r": 469,
    "category": 1,
    "company": "Intra-Cellular Therapies",
    "dates_clean": "2019-12-23",
    "brand_name": "caplyta",
    "condition": "Schizophrenia",
    "description": "Caplyta (lumateperone) is first-in-class antipsychotic for the treatment of schizophrenia.",
    "middle_radius": 235,
    "inner_radius": 235
  },
  {
    "x": 2018.75,
    "y": 100,
    "r": 173,
    "category": 1,
    "company": "Ionis Pharmaceuticals",
    "dates_clean": "2018-10-05",
    "brand_name": "Tegsedi",
    "condition": "Amyloidogenic Transthyretin Amyloidosis",
    "description": "Tegsedi (inotersen) is an antisense oligonucleotide inhibitor of the transthyretin (TTR) protein for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.",
    "middle_radius": 60,
    "inner_radius": 60
  },
  {
    "x": 2015.9167,
    "y": 100,
    "r": 1213,
    "category": 8,
    "company": "Ironwood Pharmaceuticals",
    "dates_clean": "2015-12-22",
    "brand_name": "Zurampic",
    "condition": "Hyperuricemia Associated with Gout",
    "description": "Zurampic (lesinurad) is a URAT1 inhibitor indicated for the combination treatment of hyperuricemia associated with gout.",
    "middle_radius": 405,
    "inner_radius": 405
  },
  {
    "x": 2017.5,
    "y": 100,
    "r": 1829,
    "category": 7,
    "company": "Janssen",
    "dates_clean": "2017-07-13",
    "brand_name": "Tremfya",
    "condition": "Plaque Psoriasis",
    "description": "Tremfya (guselkumab) is an interleukin-23 blocker indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.",
    "middle_radius": 1004,
    "inner_radius": 422
  },
  {
    "x": 2015.8333,
    "y": 100,
    "r": 148,
    "category": 7,
    "company": "Janssen",
    "dates_clean": "2015-11-16",
    "brand_name": "Darzalex",
    "condition": "Multiple Myeloma",
    "description": "Darzalex (daratumumab) is a human anti-CD38 monoclonal antibody indicated for the treatment of patients with multiple myeloma.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2015.75,
    "y": 100,
    "r": 518,
    "category": 7,
    "company": "Janssen",
    "dates_clean": "2015-10-23",
    "brand_name": "Yondelis",
    "condition": "Soft Tissue Sarcoma",
    "description": "Yondelis (trabectedin) is a cytotoxic antitumor agent for the treatment of unresectable or metastatic liposarcoma or leiomyosarcoma, two common subtypes of soft tissue sarcoma.\r\r\r\r",
    "middle_radius": 173,
    "inner_radius": 0
  },
  {
    "x": 2013.8333,
    "y": 100,
    "r": 111,
    "category": 7,
    "company": "Janssen",
    "dates_clean": "2013-11-13",
    "brand_name": "Imbruvica",
    "condition": "Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia; Waldenstrí_mäó»s Macroglobulinemia; Small Lymphocytic Lymphoma; Marginal Zone Lymphoma; Chronic Graft Versus Host Disease",
    "description": "Imbruvica (ibrutinib) is an oral Bruton's tyrosine kinase (BTK) inhibitor for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, Waldenstrí_mäó»s macroglobulinemia, small lymphocytic lymphoma, marginal zone lymphoma, and chronic graft versus host disease.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2019.25,
    "y": 100,
    "r": 87,
    "category": 7,
    "company": "Janssen",
    "dates_clean": "2019-04-12",
    "brand_name": "Balversa",
    "condition": "Urothelial Carcinoma",
    "description": "Balversa (erdafitinib) is a once-daily, oral, pan-fibroblast growth factor receptor for the treatment of patients with locally advanced or metastatic urothelial cancer.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2018.0833,
    "y": 100,
    "r": 1207,
    "category": 7,
    "company": "Janssen",
    "dates_clean": "2018-02-14",
    "brand_name": "Erleada",
    "condition": "Prostate Cancer",
    "description": "Erleada (apalutamide) is an oral androgen receptor inhibitor for the treatment of metastatic castration-sensitive prostate cancer, and non-metastatic castration-resistant prostate cancer.",
    "middle_radius": 401,
    "inner_radius": 401
  },
  {
    "x": 2011.5,
    "y": 100,
    "r": 9011,
    "category": 3,
    "company": "Janssen",
    "dates_clean": "2011-07-01",
    "brand_name": "Xarelto",
    "condition": "Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery, Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery, Prevention of Thromboembolism in Atrial Fibrillation, Coronary Artery Disease, Peripheral Arterial Disease, Deep Vein Thrombosis, Pulmonary Embolism",
    "description": "Xarelto (rivaroxaban) is a factor Xa inhibitor indicated in the prevention of venous thromboembolism in adult patients after total hip replacement or total knee replacement surgery.",
    "middle_radius": 4524,
    "inner_radius": 0
  },
  {
    "x": 2014.25,
    "y": 100,
    "r": 79,
    "category": 7,
    "company": "Janssen",
    "dates_clean": "2014-04-22",
    "brand_name": "Sylvant",
    "condition": "Multicentric Castleman's Disease",
    "description": "Sylvant (siltuximab) is an interleukin-6 (IL-6) antagonist indicated for the treatment of patients with multicentric Castlemanäó»s disease.",
    "middle_radius": 26,
    "inner_radius": 26
  },
  {
    "x": 2013.8333,
    "y": 100,
    "r": 1442,
    "category": 6,
    "company": "Janssen",
    "dates_clean": "2013-11-22",
    "brand_name": "Olysio",
    "condition": "Chronic Hepatitis C",
    "description": "Olysio (simeprevir) is a protease inhibitor for the treatment of chronic hepatitis C virus infection.",
    "middle_radius": 463,
    "inner_radius": 463
  },
  {
    "x": 2013.1667,
    "y": 100,
    "r": 6236,
    "category": 2,
    "company": "Janssen",
    "dates_clean": "2013-03-29",
    "brand_name": "Invokana",
    "condition": "Diabetes Type 2, Cardiovascular Risk Reduction, Diabetic Nephropathy",
    "description": "Invokana (canagliflozin) is a selective sodium glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.",
    "middle_radius": 2071,
    "inner_radius": 1211
  },
  {
    "x": 2012.9167,
    "y": 100,
    "r": 207,
    "category": 6,
    "company": "Janssen",
    "dates_clean": "2012-12-28",
    "brand_name": "Sirturo",
    "condition": "Tuberculosis -- Resistant",
    "description": "Sirturo (bedaquiline) is an oral diarylquinoline antimycobacterial drug indicated for the treatment of pulmonary multi-drug resistant tuberculosis.",
    "middle_radius": 105,
    "inner_radius": 105
  },
  {
    "x": 2011.8333,
    "y": 100,
    "r": 35,
    "category": 7,
    "company": "Jazz Pharmaceuticals",
    "dates_clean": "2011-11-18",
    "brand_name": "Erwinaze",
    "condition": "Acute Lymphoblastic Leukemia",
    "description": "Erwinaze (asparaginase Erwinia chrysanthemi) is an antineoplastic agent used to treat patients with acute lymphoblastic leukemia (ALL) who have developed an allergy (hypersensitivity) to E. coli derived asparaginase and pegapargase chemotherapy drugs.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2019.1667,
    "y": 100,
    "r": 918,
    "category": 1,
    "company": "Jazz Pharmaceuticals",
    "dates_clean": "2019-03-20",
    "brand_name": "Sunosi",
    "condition": "Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome",
    "description": "Sunosi (solriamfetol) is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) for the treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).",
    "middle_radius": 375,
    "inner_radius": 375
  },
  {
    "x": 2016.1667,
    "y": 100,
    "r": 177,
    "category": 3,
    "company": "Jazz Pharmaceuticals",
    "dates_clean": "2016-03-30",
    "brand_name": "Defitelio",
    "condition": "Hepatic Veno-Occlusive Disease",
    "description": "Defitelio (defibrotide sodium) is a deoxyribonucleic acid derivative anticoagulant for the treatment of patients with hepatic veno-occlusive disease (VOD) with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2019.5,
    "y": 100,
    "r": 83,
    "category": 7,
    "company": "Karyopharm Therapeutics",
    "dates_clean": "2019-07-03",
    "brand_name": "Xpovio",
    "condition": "Multiple Myeloma",
    "description": "Xpovio (selinexor) is a first in class Selective Inhibitor of Nuclear Export (SINE) XPO1 antagonist for the treatment of patients adult patients with relapsed or refractory multiple myeloma (RRMM).",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2013,
    "y": 100,
    "r": 51,
    "category": 4,
    "company": "Kastle Therapeutics",
    "dates_clean": "2013-01-29",
    "brand_name": "Kynamro",
    "condition": "Homozygous Familial Hypercholesterolemia",
    "description": "Kynamro (mipomersen) is an oligonucleotide inhibitor of apolipoprotein B-100 synthesis indicated for the treatment of patients with homozygous familial hypercholesterolemia.",
    "middle_radius": 17,
    "inner_radius": 17
  },
  {
    "x": 2018.5833,
    "y": 100,
    "r": 372,
    "category": 7,
    "company": "Kyowa Kirin",
    "dates_clean": "2018-08-08",
    "brand_name": "Poteligeo",
    "condition": "Mycosis Fungoides; Sí©zary Syndrome",
    "description": "Poteligeo (mogamulizumab-kpkc) is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sí©zary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma (CTCL).\r\r",
    "middle_radius": 186,
    "inner_radius": 0
  },
  {
    "x": 2019.5833,
    "y": 100,
    "r": 1143,
    "category": 1,
    "company": "Kyowa Kirin",
    "dates_clean": "2019-08-27",
    "brand_name": "Nourianz",
    "condition": "Parkinson's Disease",
    "description": "Nourianz (istradefylline) is an adenosine A2A receptor antagonist indicated for use as an adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsonäó»s disease (PD) experiencing äóìOFFäó episodes.",
    "middle_radius": 420,
    "inner_radius": 420
  },
  {
    "x": 2017.9167,
    "y": 100,
    "r": 321,
    "category": 4,
    "company": "La Jolla Pharmaceutical Company",
    "dates_clean": "2017-12-21",
    "brand_name": "Giapreza",
    "condition": "Hypotension, Shock",
    "description": "Giapreza (angiotensin II) is a synthetic human angiotensin II vasoconstrictor indicated for the treatment of hypotension in adults with septic or other distributive shock.",
    "middle_radius": 158,
    "inner_radius": 158
  },
  {
    "x": 2018.75,
    "y": 100,
    "r": 10,
    "category": 7,
    "company": "Leadiant Biosciences",
    "dates_clean": "2018-10-05",
    "brand_name": "Revcovi",
    "condition": "Adenosine Deaminase Severe Combined Immune",
    "description": "Revcovi (elapegademase-lvlr) is a recombinant adenosine deaminase indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID).",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2012,
    "y": 100,
    "r": 1005,
    "category": 5,
    "company": "Leo Pharma",
    "dates_clean": "2012-01-23",
    "brand_name": "Picato",
    "condition": "Actinic Keratosis",
    "description": "Picato (ingenol mebutate) is an inducer of cell death indicated for the topical treatment of actinic keratosis.",
    "middle_radius": 502,
    "inner_radius": 502
  },
  {
    "x": 2017.0833,
    "y": 100,
    "r": 90,
    "category": 2,
    "company": "Lexicon Pharmaceuticals",
    "dates_clean": "2017-02-28",
    "brand_name": "Xermelo",
    "condition": "Carcinoid Syndrome Diarrhea",
    "description": "Xermelo (telotristat ethyl) is an oral tryptophan hydroxylase inhibitor indicated for use in combination with somatostatin analog (SSA) therapy for the treatment of carcinoid syndrome diarrhea in patients with metastatic neuroendocrine tumors.",
    "middle_radius": 45,
    "inner_radius": 45
  },
  {
    "x": 2018.8333,
    "y": 100,
    "r": 55,
    "category": 7,
    "company": "Loxo Oncology",
    "dates_clean": "2018-11-26",
    "brand_name": "Vitrakvi",
    "condition": "TRK Fusion Cancers",
    "description": "Vitrakvi (larotrectinib) is an oral selective tropomyosin receptor kinase (TRK) inhibitor for the treatment solid tumors harboring NTRK-fusion proteins.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2011.75,
    "y": 100,
    "r": 285,
    "category": 1,
    "company": "Lundbeck",
    "dates_clean": "2011-10-21",
    "brand_name": "Onfi",
    "condition": "Lennox-Gastaut Syndrome",
    "description": "Onfi (clobazam) is a benzodiazepine antiepileptic drug for the treatment of patients with Lennox-Gastaut syndrome (LGS).",
    "middle_radius": 57,
    "inner_radius": 57
  },
  {
    "x": 2018.4167,
    "y": 100,
    "r": 1472,
    "category": 10,
    "company": "Medicines Development for Global Health",
    "dates_clean": "2018-06-13",
    "brand_name": "moxidectin",
    "condition": "Onchocerciasis",
    "description": "Moxidectin is a macrocyclic lactone anthelmintic medicine indicated for the treatment of river blindness (onchocerciasis) in patients aged 12 years and older.",
    "middle_radius": 495,
    "inner_radius": 0
  },
  {
    "x": 2017.9167,
    "y": 100,
    "r": 723,
    "category": 5,
    "company": "Medimetriks Pharmaceuticals",
    "dates_clean": "2017-12-11",
    "brand_name": "Xepi",
    "condition": "Impetigo",
    "description": "Xepi (ozenoxacin) is a topical non-fluorinated quinolone for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.",
    "middle_radius": 362,
    "inner_radius": 362
  },
  {
    "x": 2017.4167,
    "y": 100,
    "r": 1510,
    "category": 6,
    "company": "Melinta Therapeutics",
    "dates_clean": "2017-06-19",
    "brand_name": "Baxdela",
    "condition": "Skin and Structure Infection, Pneumonia",
    "description": "Baxdela (delafloxacin) is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria.",
    "middle_radius": 756,
    "inner_radius": 0
  },
  {
    "x": 2019.5,
    "y": 100,
    "r": 0,
    "category": 6,
    "company": "Merck",
    "dates_clean": "2019-07-16",
    "brand_name": "Recarbrio",
    "condition": "Urinary Tract Infection, Intraabdominal Infection",
    "description": "Recarbrio (imipenem, cilastatin, and relebactam) is a combination of imipenem, a penem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a betalactamase inhibitor, indicated for the treatment of complicated urinary tract infections and complicated intra-abdominal infections (cIAI).",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2018.5833,
    "y": 100,
    "r": 1494,
    "category": 6,
    "company": "Merck",
    "dates_clean": "2018-08-30",
    "brand_name": "Pifeltro",
    "condition": "HIV Infection",
    "description": "Pifeltro (doravirine) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for the treatment of HIV-1 infection.",
    "middle_radius": 747,
    "inner_radius": 0
  },
  {
    "x": 2017.9167,
    "y": 100,
    "r": 4847,
    "category": 2,
    "company": "Merck",
    "dates_clean": "2017-12-19",
    "brand_name": "Steglatro",
    "condition": "Diabetes Type 2",
    "description": "Steglatro (ertugliflozin) is a sodium-glucose co-transporter-2 (SGLT2) inhibitor used to help improve glycemic control in adults with type 2 diabetes.",
    "middle_radius": 1447,
    "inner_radius": 763
  },
  {
    "x": 2014.3333,
    "y": 100,
    "r": 20170,
    "category": 3,
    "company": "Merck",
    "dates_clean": "2014-05-08",
    "brand_name": "Zontivity",
    "condition": "Cardiovascular Risk Reduction",
    "description": "Zontivity (vorapaxar) is a protease-activated receptor-1 (PAR-1) antagonist for the prevention of cardiovascular events in high risk patients.",
    "middle_radius": 10090,
    "inner_radius": 10090
  },
  {
    "x": 2011.3333,
    "y": 100,
    "r": 1500,
    "category": 6,
    "company": "Merck",
    "dates_clean": "2011-05-13",
    "brand_name": "Victrelis",
    "condition": "Chronic Hepatitis C",
    "description": "Victrelis (boceprevir) is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated for the treatment of chronic hepatitis C.",
    "middle_radius": 443,
    "inner_radius": 0
  },
  {
    "x": 2017.8333,
    "y": 100,
    "r": 495,
    "category": 6,
    "company": "Merck",
    "dates_clean": "2017-11-08",
    "brand_name": "Prevymis",
    "condition": "CMV Prophylaxis",
    "description": "Prevymis (letermovir) is a CMV DNA terminase complex inhibitor indicated for the prophylaxis of cytomegalovirus (CMV) infection and disease in adult allogeneic hematopoietic stem cell transplant patients.",
    "middle_radius": 170,
    "inner_radius": 170
  },
  {
    "x": 2016.75,
    "y": 100,
    "r": 1554,
    "category": 6,
    "company": "Merck",
    "dates_clean": "2016-10-21",
    "brand_name": "Zinplava",
    "condition": "Prevention of Clostridium Difficile Infection Recurrence",
    "description": "Zinplava (bezlotoxumab) is a selective, fully-human, monoclonal antibody that binds to Clostridium difficile toxin B, indicated to reduce recurrence of Clostridium difficile infection (CDI) in patients 18 years of age or older.",
    "middle_radius": 773,
    "inner_radius": 773
  },
  {
    "x": 2016,
    "y": 100,
    "r": 1274,
    "category": 6,
    "company": "Merck",
    "dates_clean": "2016-01-28",
    "brand_name": "Zepatier",
    "condition": "Chronic Hepatitis C",
    "description": "Zepatier (elbasvir and grazoprevir) is a once-daily, single tablet, NS5A replication complex inhibitor and NS3/4A protease inhibitor combination for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections.",
    "middle_radius": 215,
    "inner_radius": 215
  },
  {
    "x": 2015.9167,
    "y": 100,
    "r": 346,
    "category": 10,
    "company": "Merck",
    "dates_clean": "2015-12-15",
    "brand_name": "Bridion",
    "condition": "Reversal of Nondepolarizing Muscle Relaxants",
    "description": "Bridion (sugammadex) is a novel selective relaxant binding agent (SRBA) for the reversal of neuromuscular blockade induced by rocuronium or vecuronium.",
    "middle_radius": 173,
    "inner_radius": 0
  },
  {
    "x": 2014.6667,
    "y": 100,
    "r": 173,
    "category": 7,
    "company": "Merck",
    "dates_clean": "2014-09-04",
    "brand_name": "Keytruda",
    "condition": "Melanoma -- Metastatic, Non-Small Cell Lung Cancer, Head and Neck Cancer, Hodgkin's Disease, Urothelial Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Renal Cell Carcinoma, Small Cell Lung Cancer, Esophageal Carcinoma, Endometrial Carcinoma",
    "description": "Keytruda (pembrolizumab) is a human PD-1 (programmed death receptor-1)-blocking antibody indicated for the treatment of melanoma, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, microsatellite instability-high cancer, gastric cancer, esophageal cancer, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, renal cell carcinoma, and endometrial carcinoma.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2012.0833,
    "y": 100,
    "r": 1816,
    "category": 10,
    "company": "Merck",
    "dates_clean": "2012-02-10",
    "brand_name": "Zioptan",
    "condition": "Glaucoma (Open Angle), Intraocular Hypertension",
    "description": "Zioptan (tafluprost ophthalmic solution) is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.",
    "middle_radius": 854,
    "inner_radius": 0
  },
  {
    "x": 2014.5833,
    "y": 100,
    "r": 1260,
    "category": 1,
    "company": "Merck, Sharpe & Dohme Corp.",
    "dates_clean": "2014-08-13",
    "brand_name": "Belsomra",
    "condition": "Insomnia",
    "description": "Belsomra (suvorexant) is an orexin receptor antagonist for use in patients with difficulty falling or staying asleep (insomnia).",
    "middle_radius": 767,
    "inner_radius": 767
  },
  {
    "x": 2010.5,
    "y": 100,
    "r": 342,
    "category": 8,
    "company": "Merz Pharmaceuticals",
    "dates_clean": "2010-07-30",
    "brand_name": "Xeomin",
    "condition": "Cervical Dystonia, Blepharospasm, Glabellar Lines, Upper Limb Spasticity, Excessive Salivation",
    "description": "Xeomin (incobotulinumtoxinA) is a botulinum toxin type A for the treatment of cervical dystonia, blepharospasm, glabellar lines, upper limb spasticity, and excessive drooling.",
    "middle_radius": 108,
    "inner_radius": 108
  },
  {
    "x": 2017.3333,
    "y": 100,
    "r": 137,
    "category": 1,
    "company": "Mitsubishi Tanabe Pharma",
    "dates_clean": "2017-05-05",
    "brand_name": "Radicava",
    "condition": "Amyotrophic Lateral Sclerosis",
    "description": "Radicava (edaravone) is a free radical scavenger that relieves the effects of oxidative stress, a likely factor in the onset and progression of amyotrophic lateral sclerosis.",
    "middle_radius": 68,
    "inner_radius": 68
  },
  {
    "x": 2010.8333,
    "y": 100,
    "r": 762,
    "category": 7,
    "company": "Eisai",
    "dates_clean": "2010-11-15",
    "brand_name": "Halaven",
    "condition": "Breast Cancer",
    "description": "Halaven (eribulin mesylate) is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer, and liposarcoma.",
    "middle_radius": 254,
    "inner_radius": 0
  },
  {
    "x": 2019.5833,
    "y": 100,
    "r": 1289,
    "category": 6,
    "company": "Nabriva Therapeutics",
    "dates_clean": "2019-08-19",
    "brand_name": "Xenleta",
    "condition": "Pneumonia",
    "description": "Xenleta (lefamulin) is a first-in-class, semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia (CABP).",
    "middle_radius": 643,
    "inner_radius": 0
  },
  {
    "x": 2012.9167,
    "y": 100,
    "r": 749,
    "category": 2,
    "company": "Napo Pharmaceuticals",
    "dates_clean": "2012-12-31",
    "brand_name": "Mytesi",
    "condition": "Diarrhea",
    "description": "Mytesi (crofelemer) is a proanthocyanidin oligomer indicated to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy.",
    "middle_radius": 231,
    "inner_radius": 231
  },
  {
    "x": 2017.25,
    "y": 100,
    "r": 234,
    "category": 1,
    "company": "Neurocrine Biosciences",
    "dates_clean": "2017-04-11",
    "brand_name": "Ingrezza",
    "condition": "Tardive Dyskinesia",
    "description": "Ingrezza (valbenazine) is a novel, highly-selective VMAT2 inhibitor for the treatment of tardive dyskinesia.\r\r\r\r",
    "middle_radius": 78,
    "inner_radius": 78
  },
  {
    "x": 2017.1667,
    "y": 100,
    "r": 1194,
    "category": 1,
    "company": "Newron Pharmaceuticals",
    "dates_clean": "2017-03-21",
    "brand_name": "Xadago",
    "condition": "Parkinson's Disease",
    "description": "Xadago (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinsonäó»s disease (PD) experiencing äóìoffäó episodes.",
    "middle_radius": 487,
    "inner_radius": 487
  },
  {
    "x": 2019.8333,
    "y": 100,
    "r": 198,
    "category": 3,
    "company": "Novartis",
    "dates_clean": "2019-11-15",
    "brand_name": "Adakveo",
    "condition": "Prevention of Vaso-Occlusive Crises (VOCs) in Sickle Cell Disease",
    "description": "Adakveo (crizanlizumab-tmca) is a P-selectin inhibitor for the prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease (SCD).",
    "middle_radius": 65,
    "inner_radius": 65
  },
  {
    "x": 2019.75,
    "y": 100,
    "r": 1459,
    "category": 10,
    "company": "Novartis",
    "dates_clean": "2019-10-07",
    "brand_name": "Beovu",
    "condition": "Macular Degeneration",
    "description": "Beovu (brolucizumab-dbll) is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD).",
    "middle_radius": 729,
    "inner_radius": 729
  },
  {
    "x": 2019.3333,
    "y": 100,
    "r": 341,
    "category": 7,
    "company": "Novartis",
    "dates_clean": "2019-05-24",
    "brand_name": "Piqray",
    "condition": "Breast Cancer",
    "description": "Piqray (alpelisib) is a kinase inhibitor indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR positive, HER2-negative, PIK3CA-mutated breast cancer.",
    "middle_radius": 172,
    "inner_radius": 172
  },
  {
    "x": 2019.1667,
    "y": 100,
    "r": 1645,
    "category": 7,
    "company": "Novartis",
    "dates_clean": "2019-03-26",
    "brand_name": "Mayzent",
    "condition": "Multiple Sclerosis",
    "description": "Mayzent (siponimod) is a sphingosine-1-phosphate receptor modulator for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.",
    "middle_radius": 546,
    "inner_radius": 546
  },
  {
    "x": 2019.0833,
    "y": 100,
    "r": 466,
    "category": 10,
    "company": "Novartis",
    "dates_clean": "2019-02-13",
    "brand_name": "Egaten",
    "condition": "Fascioliasis",
    "description": "Egaten (triclabendazole) is a benzimidazole anthelmintic indicated for the treatment of fascioliasis,  a neglected tropical disease (NTD) caused by liver flukes Fasciola hepatica and Fasciola gigantica.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2017.25,
    "y": 100,
    "r": 833,
    "category": 7,
    "company": "Novartis",
    "dates_clean": "2017-04-28",
    "brand_name": "Rydapt",
    "condition": "Acute Myeloid Leukemia, Mastocytosis",
    "description": "Rydapt (midostaurin) is an oral, multi-targeted kinase inhibitor for the treatment of acute myeloid leukemia (AML) in newly-diagnosed adults with an FMS-like tyrosine kinase-3 (FLT3) mutation, and for the treatment of advanced systemic mastocytosis (SM), which includes aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN) and mast cell leukemia.",
    "middle_radius": 357,
    "inner_radius": 357
  },
  {
    "x": 2010.6667,
    "y": 100,
    "r": 2554,
    "category": 7,
    "company": "Novartis",
    "dates_clean": "2010-09-21",
    "brand_name": "Gilenya",
    "condition": "Multiple Sclerosis",
    "description": "Gilenya (fingolimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis.",
    "middle_radius": 853,
    "inner_radius": 853
  },
  {
    "x": 2011.5,
    "y": 100,
    "r": 5451,
    "category": 9,
    "company": "Novartis",
    "dates_clean": "2011-07-01",
    "brand_name": "Arcapta",
    "condition": "Chronic Obstructive Pulmonary Disease",
    "description": "Arcapta (indacaterol inhalation powder) is a long-acting beta2-agonist (LABA) for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).",
    "middle_radius": 2681,
    "inner_radius": 1289
  },
  {
    "x": 2017.1667,
    "y": 100,
    "r": 668,
    "category": 7,
    "company": "Novartis",
    "dates_clean": "2017-03-13",
    "brand_name": "Kisqali",
    "condition": "Breast Cancer",
    "description": "Kisqali (ribociclib) is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6 indicated for the combination treatment of pre/perimenopausal or postmenopausal women with HR+/HER2- metastatic breast cancer.\r\r",
    "middle_radius": 334,
    "inner_radius": 334
  },
  {
    "x": 2015.5,
    "y": 100,
    "r": 230,
    "category": 7,
    "company": "Novartis",
    "dates_clean": "2015-07-24",
    "brand_name": "Odomzo",
    "condition": "Basal Cell Carcinoma",
    "description": "Odomzo (sonidegib) is a hedgehog pathway inhibitor indicated for the treatment of locally advanced basal cell carcinoma (BCC).",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2015.5,
    "y": 100,
    "r": 8399,
    "category": 4,
    "company": "Novartis",
    "dates_clean": "2015-07-07",
    "brand_name": "Entresto",
    "condition": "Heart Failure",
    "description": "Entresto (sacubitril and valsartan) is a neprilysin inhibitor and angiotensin II receptor blocker combination used to reduce the risk of hospitalization in people with certain types of long-lasting (chronic) heart failure.",
    "middle_radius": 4212,
    "inner_radius": 0
  },
  {
    "x": 2015.0833,
    "y": 100,
    "r": 768,
    "category": 7,
    "company": "Novartis",
    "dates_clean": "2015-02-23",
    "brand_name": "Farydak",
    "condition": "Multiple Myeloma",
    "description": "Farydak (panobinostat) is a histone deacetylase inhibitor for the combination treatment of multiple myeloma.",
    "middle_radius": 381,
    "inner_radius": 381
  },
  {
    "x": 2015,
    "y": 100,
    "r": 2400,
    "category": 7,
    "company": "Novartis",
    "dates_clean": "2015-01-21",
    "brand_name": "Cosentyx",
    "condition": "Plaque Psoriasis, Ankylosing Spondylitis, Psoriatic Arthritis",
    "description": "Cosentyx (secukinumab) is a selective interleukin-17A (IL-17A) inhibitor for the treatment of plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis.",
    "middle_radius": 1017,
    "inner_radius": 694
  },
  {
    "x": 2014.25,
    "y": 100,
    "r": 163,
    "category": 7,
    "company": "Novartis",
    "dates_clean": "2014-04-29",
    "brand_name": "Zykadia",
    "condition": "Non-Small Cell Lung Cancer",
    "description": "Zykadia (ceritinib) is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2018.8333,
    "y": 100,
    "r": 27,
    "category": 7,
    "company": "Novimmune SA",
    "dates_clean": "2018-11-20",
    "brand_name": "Gamifant",
    "condition": "Hemophagocytic Lymphohistiocytosis",
    "description": "Gamifant (emapalumab-lzsg) is an interferon gamma (IFN‘_) blocking antibody for the treatment of patients with primary hemophagocytic lymphohistiocytosis (HLH).",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2017.9167,
    "y": 100,
    "r": 7196,
    "category": 2,
    "company": "Novo Nordisk",
    "dates_clean": "2017-12-05",
    "brand_name": "Ozempic",
    "condition": "Diabetes Type 2",
    "description": "Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) analog administered once-weekly for the treatment of adults with type 2 diabetes.",
    "middle_radius": 3083,
    "inner_radius": 1911
  },
  {
    "x": 2015.6667,
    "y": 100,
    "r": 1084,
    "category": 2,
    "company": "Novo Nordisk",
    "dates_clean": "2015-09-25",
    "brand_name": "Tresiba",
    "condition": "Diabetes Type 1, Diabetes Type 2",
    "description": "Tresiba (insulin degludec) is a long-acting basal insulin analogue indicated to improve glycemic control in patients one year of age and older with diabetes mellitus.",
    "middle_radius": 310,
    "inner_radius": 0
  },
  {
    "x": 2013.75,
    "y": 100,
    "r": 213,
    "category": 3,
    "company": "Novo Nordisk",
    "dates_clean": "2013-10-15",
    "brand_name": "Novoeight",
    "condition": "Hemophilia A",
    "description": "Novoeight (turoctocog alfa) is an antihemophilic factor (recombinant) indicated for use in adults and children with hemophilia A.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2010,
    "y": 100,
    "r": 3978,
    "category": 2,
    "company": "Novo Nordisk",
    "dates_clean": "2010-01-25",
    "brand_name": "Victoza",
    "condition": "Diabetes Type 2",
    "description": "Victoza (liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus, and to reduce the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.",
    "middle_radius": 1477,
    "inner_radius": 524
  },
  {
    "x": 2015,
    "y": 100,
    "r": 124,
    "category": 10,
    "company": "NPS Pharmaceuticals",
    "dates_clean": "2015-01-23",
    "brand_name": "Natpara",
    "condition": "Hypoparathyroidism",
    "description": "Natpara (parathyroid hormone) is recombinant human parathyroid hormone 1-84 indicated to control hypocalcemia in patients with hypoparathyroidism.",
    "middle_radius": 40,
    "inner_radius": 40
  },
  {
    "x": 2011.3333,
    "y": 100,
    "r": 1105,
    "category": 2,
    "company": "Optimer Pharmaceuticals",
    "dates_clean": "2011-05-27",
    "brand_name": "Dificid",
    "condition": "Clostridial Infection",
    "description": "Dificid (fidaxomicin) is a macrolide antibacterial drug indicated for the treatment of Clostridium difficile-associated diarrhea.",
    "middle_radius": 563,
    "inner_radius": 0
  },
  {
    "x": 2010.1667,
    "y": 100,
    "r": 23,
    "category": 2,
    "company": "Orphan Europe",
    "dates_clean": "2010-03-18",
    "brand_name": "Carbaglu",
    "condition": "NAGS Deficiency Hyperammonemia",
    "description": "Carbaglu (carglumic acid) is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated for the treatment of hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS).",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2015.5,
    "y": 100,
    "r": 980,
    "category": 1,
    "company": "Otsuka Pharmaceutical",
    "dates_clean": "2015-07-10",
    "brand_name": "Rexulti",
    "condition": "Schizophrenia; Major Depressive Disorder",
    "description": "Rexulti (brexpiprazole) is a serotonin-dopamine activity modulator (SDAM) for the treatment of schizophrenia and the adjunctive treatment of major depressive disorder.",
    "middle_radius": 381,
    "inner_radius": 381
  },
  {
    "x": 2014.1667,
    "y": 100,
    "r": 610,
    "category": 7,
    "company": "Paladin Labs",
    "dates_clean": "2014-03-19",
    "brand_name": "Impavido",
    "condition": "Leishmaniasis",
    "description": "Impavido (miltefosine) is an oral alkylphosphocholine antiparasitic for the treatment of leishmaniasis.",
    "middle_radius": 143,
    "inner_radius": 44
  },
  {
    "x": 2011,
    "y": 100,
    "r": 1038,
    "category": 10,
    "company": "ParaPRO",
    "dates_clean": "2011-01-18",
    "brand_name": "Natroba",
    "condition": "Lice",
    "description": "Natroba (spinosad) is a pediculicide indicated for the topical treatment of head lice infestations.",
    "middle_radius": 486,
    "inner_radius": 486
  },
  {
    "x": 2018.75,
    "y": 100,
    "r": 2164,
    "category": 6,
    "company": "Paratek Pharmaceuticals",
    "dates_clean": "2018-10-02",
    "brand_name": "Nuzyra",
    "condition": "Skin and Structure Infection, Pneumonia",
    "description": "Nuzyra (omadacycline) is an aminomethylcycline tetracycline antibiotic for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).",
    "middle_radius": 1081,
    "inner_radius": 0
  },
  {
    "x": 2019.3333,
    "y": 100,
    "r": 441,
    "category": 1,
    "company": "Pfizer",
    "dates_clean": "2019-05-03",
    "brand_name": "Vyndaqel",
    "condition": "Cardiomyopathy of Transthyretin-Mediated Amyloidosis",
    "description": "Vyndaqel (tafamidis meglumine) is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis.",
    "middle_radius": 177,
    "inner_radius": 177
  },
  {
    "x": 2018.8333,
    "y": 100,
    "r": 115,
    "category": 7,
    "company": "Pfizer",
    "dates_clean": "2018-11-21",
    "brand_name": "Daurismo",
    "condition": "Acute Myeloid Leukemia",
    "description": "Daurismo (glasdegib) is a hedgehog pathway inhibitor indicated for the combination treatment of adult patients äŠ«75 years with newly-diagnosed acute myeloid leukemia (AML).",
    "middle_radius": 38,
    "inner_radius": 0
  },
  {
    "x": 2018.8333,
    "y": 100,
    "r": 215,
    "category": 7,
    "company": "Pfizer",
    "dates_clean": "2018-11-02",
    "brand_name": "Lorbrena",
    "condition": "Non-Small Cell Lung Cancer",
    "description": "Lorbrena (lorlatinib) is an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC).",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2018.75,
    "y": 100,
    "r": 431,
    "category": 7,
    "company": "Pfizer",
    "dates_clean": "2018-10-16",
    "brand_name": "Talzenna",
    "condition": "Breast Cancer",
    "description": "Talzenna (talazoparib) is an oral poly ADP ribose polymerase (PARP) inhibitor indicated for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.",
    "middle_radius": 144,
    "inner_radius": 0
  },
  {
    "x": 2018.6667,
    "y": 100,
    "r": 452,
    "category": 7,
    "company": "Pfizer",
    "dates_clean": "2018-09-27",
    "brand_name": "Vizimpro",
    "condition": "Non-Small Cell Lung Cancer",
    "description": "Vizimpro (dacomitinib) is an oral, once-daily, irreversible pan-human epidermal growth factor receptor tyrosine kinase inhibitor (TKI) indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.",
    "middle_radius": 225,
    "inner_radius": 0
  },
  {
    "x": 2017.5833,
    "y": 100,
    "r": 326,
    "category": 7,
    "company": "Pfizer",
    "dates_clean": "2017-08-17",
    "brand_name": "Besponsa",
    "condition": "Acute Lymphoblastic Leukemia",
    "description": "Besponsa (inotuzumab ozogamicin) is a CD22 monoclonal antibody and calicheamicin cytotoxic agent conjugate for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).\r\r\r\r\r\r\r\r\r\r",
    "middle_radius": 162,
    "inner_radius": 0
  },
  {
    "x": 2015.0833,
    "y": 100,
    "r": 165,
    "category": 7,
    "company": "Pfizer",
    "dates_clean": "2015-02-03",
    "brand_name": "Ibrance",
    "condition": "Breast Cancer",
    "description": "Ibrance (palbociclib) is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with hormone therapy.",
    "middle_radius": 81,
    "inner_radius": 0
  },
  {
    "x": 2013.75,
    "y": 100,
    "r": 686,
    "category": 10,
    "company": "Pfizer",
    "dates_clean": "2013-10-03",
    "brand_name": "Duavee",
    "condition": "Postmenopausal Symptoms, Prevention of Osteoporosis",
    "description": "Duavee (bazedoxifene and conjugated estrogens) is an estrogen agonist/antagonist and conjugated estrogens combination indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause, and prevention of postmenopausal osteoporosis in women with an intact uterus.",
    "middle_radius": 309,
    "inner_radius": 309
  },
  {
    "x": 2012.8333,
    "y": 100,
    "r": 3322,
    "category": 7,
    "company": "Pfizer",
    "dates_clean": "2012-11-06",
    "brand_name": "Xeljanz",
    "condition": "Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis",
    "description": "Xeljanz (tofacitinib) is an oral Janus kinase (JAK) inhibitor for the treatment of adult patients with moderately to severely active rheumatoid arthritis, active psoriatic arthritis, and moderately to severely active ulcerative colitis.",
    "middle_radius": 885,
    "inner_radius": 681
  },
  {
    "x": 2012.6667,
    "y": 100,
    "r": 546,
    "category": 7,
    "company": "Pfizer",
    "dates_clean": "2012-09-04",
    "brand_name": "Bosulif",
    "condition": "Chronic Myelogenous Leukemia",
    "description": "Bosulif (bosutinib) is a kinase inhibitor indicated for the treatment of adult patients with chronic, accelerated, or blast phase Ph+ chronic myelogenous leukemia (CML).",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2012,
    "y": 100,
    "r": 723,
    "category": 7,
    "company": "Pfizer",
    "dates_clean": "2012-01-27",
    "brand_name": "Inlyta",
    "condition": "Renal Cell Carcinoma",
    "description": "Inlyta (axitinib) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma.",
    "middle_radius": 362,
    "inner_radius": 0
  },
  {
    "x": 2011.5833,
    "y": 100,
    "r": 255,
    "category": 7,
    "company": "Pfizer",
    "dates_clean": "2011-08-26",
    "brand_name": "Xalkori",
    "condition": "Non-Small Cell Lung Cancer",
    "description": "Xalkori (crizotinib) is an oral anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive or ROS1-positive.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2016.9167,
    "y": 100,
    "r": 1522,
    "category": 5,
    "company": "Pfizer",
    "dates_clean": "2016-12-14",
    "brand_name": "Eucrisa",
    "condition": "Atopic Dermatitis",
    "description": "Eucrisa (crisaborole) is a novel, non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor indicated for the treatment of mild-to-moderate atopic dermatitis.",
    "middle_radius": 506,
    "inner_radius": 506
  },
  {
    "x": 2017.4167,
    "y": 100,
    "r": 7441,
    "category": 3,
    "company": "Portola Pharmaceuticals",
    "dates_clean": "2017-06-23",
    "brand_name": "Bevyxxa",
    "condition": "Prevention of Venous Thromboembolism",
    "description": "Bevyxxa (betrixaban) is an oral, once-daily Factor Xa inhibitor anticoagulant for the extended-duration prophylaxis of venous thromboembolism (VTE) in at-risk adult patients hospitalized for an acute medical illness.",
    "middle_radius": 3720,
    "inner_radius": 3720
  },
  {
    "x": 2012.3333,
    "y": 100,
    "r": 56,
    "category": 2,
    "company": "Protalix BioTherapeutics",
    "dates_clean": "2012-05-01",
    "brand_name": "Elelyso",
    "condition": "Gaucher Disease",
    "description": "Elelyso (taliglucerase alfa) is a plant-cell expressed recombinant form of glucocerebrosidase for the treatment of Gaucher disease.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2017.0833,
    "y": 100,
    "r": 101,
    "category": 10,
    "company": "PTC Therapeutics",
    "dates_clean": "2017-02-09",
    "brand_name": "Emflaza",
    "condition": "Duchenne Muscular Dystrophy",
    "description": "Emflaza (deflazacort) is a glucocorticoid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.",
    "middle_radius": 50,
    "inner_radius": 50
  },
  {
    "x": 2017.5,
    "y": 100,
    "r": 2840,
    "category": 7,
    "company": "Puma Biotechnology",
    "dates_clean": "2017-07-17",
    "brand_name": "Nerlynx",
    "condition": "Breast Cancer -- Adjuvant",
    "description": "Nerlynx (neratinib) is a tyrosine kinase inhibitor for the extended adjuvant treatment of early-stage HER2-positive breast cancer.",
    "middle_radius": 1420,
    "inner_radius": 1420
  },
  {
    "x": 2017.25,
    "y": 100,
    "r": 1645,
    "category": 10,
    "company": "Radius Health",
    "dates_clean": "2017-04-28",
    "brand_name": "Tymlos",
    "condition": "Osteoporosis",
    "description": "Tymlos (abaloparatide) is a synthetic peptide analog of hPTHrP (human parathyroid hormone-related protein) for the treatment of postmenopausal women with osteoporosis.",
    "middle_radius": 821,
    "inner_radius": 821
  },
  {
    "x": 2011.8333,
    "y": 100,
    "r": 2412,
    "category": 10,
    "company": "Regeneron",
    "dates_clean": "2011-11-18",
    "brand_name": "Eylea",
    "condition": "Macular Degeneration; Macular Edema; Diabetic Retinopathy; Diabetic Macular Edema",
    "description": "Eylea (aflibercept) is a VEGF inhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.",
    "middle_radius": 595,
    "inner_radius": 0
  },
  {
    "x": 2015.75,
    "y": 100,
    "r": 654,
    "category": 10,
    "company": "Relypsa",
    "dates_clean": "2015-10-21",
    "brand_name": "Veltassa",
    "condition": "Hyperkalemia",
    "description": "Veltassa (patiromer) is an oral potassium binder for the treatment of hyperkalemia.",
    "middle_radius": 52,
    "inner_radius": 0
  },
  {
    "x": 2018.25,
    "y": 100,
    "r": 150,
    "category": 3,
    "company": "Rigel Pharmaceuticals",
    "dates_clean": "2018-04-17",
    "brand_name": "Tavalisse",
    "condition": "Idiopathic (Immune) Thrombocytopenic Purpura",
    "description": "Tavalisse (fostamatinib) is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of patients with chronic immune thrombocytopenia (ITP).\r\r",
    "middle_radius": 49,
    "inner_radius": 49
  },
  {
    "x": 2019.1667,
    "y": 100,
    "r": 226,
    "category": 1,
    "company": "Sage Therapeutics",
    "dates_clean": "2019-03-19",
    "brand_name": "Zulresso",
    "condition": "Postpartum Depression",
    "description": "Zulresso (brexanolone) is a gamma-aminobutyric acid A (GABAA) receptor positive allosteric modulator indicated for the treatment of postpartum depression (PPD).",
    "middle_radius": 96,
    "inner_radius": 96
  },
  {
    "x": 2018.6667,
    "y": 100,
    "r": 108,
    "category": 7,
    "company": "Sanofi",
    "dates_clean": "2018-09-28",
    "brand_name": "Libtayo",
    "condition": "Squamous Cell Carcinoma",
    "description": "Libtayo (cemiplimab-rwlc) is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC).",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2016.5,
    "y": 100,
    "r": 5079,
    "category": 2,
    "company": "Sanofi",
    "dates_clean": "2016-07-27",
    "brand_name": "Adlyxin",
    "condition": "Diabetes Type 2",
    "description": "Adlyxin (lixisenatide) is a once-daily prandial GLP-1 receptor agonist for the treatment of adults with type 2 diabetes mellitus.",
    "middle_radius": 2385,
    "inner_radius": 1473
  },
  {
    "x": 2012.6667,
    "y": 100,
    "r": 1088,
    "category": 7,
    "company": "Sanofi",
    "dates_clean": "2012-09-12",
    "brand_name": "Aubagio",
    "condition": "Multiple Sclerosis",
    "description": "Aubagio (teriflunomide) is an oral pyrimidine synthesis inhibitor indicated for the treatment of patients with relapsing forms of multiple sclerosis.",
    "middle_radius": 363,
    "inner_radius": 363
  },
  {
    "x": 2017.1667,
    "y": 100,
    "r": 1338,
    "category": 5,
    "company": "Sanofi and Regeneron",
    "dates_clean": "2017-03-28",
    "brand_name": "Dupixent",
    "condition": "Atopic Dermatitis, Asthma",
    "description": "Dupixent (dupilumab) is an interleukin-4 receptor alpha antagonist indicated for the treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis.",
    "middle_radius": 775,
    "inner_radius": 775
  },
  {
    "x": 2017.3333,
    "y": 100,
    "r": 1743,
    "category": 7,
    "company": "Sanofi and Regeneron",
    "dates_clean": "2017-05-22",
    "brand_name": "Kevzara",
    "condition": "Rheumatoid Arthritis",
    "description": "Kevzara (sarilumab) is an interleukin-6 receptor (IL-6R) antibody for the treatment of adults with rheumatoid arthritis.",
    "middle_radius": 579,
    "inner_radius": 579
  },
  {
    "x": 2015.5,
    "y": 100,
    "r": 3499,
    "category": 4,
    "company": "Sanofi and Regeneron",
    "dates_clean": "2015-07-24",
    "brand_name": "Praluent",
    "condition": "High Cholesterol",
    "description": "Praluent (alirocumab) is a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor monoclonal antibody indicated as adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-cholesterol (LDL-C).",
    "middle_radius": 1175,
    "inner_radius": 1175
  },
  {
    "x": 2012.5833,
    "y": 100,
    "r": 1226,
    "category": 7,
    "company": "Sanofi and Regeneron",
    "dates_clean": "2012-08-03",
    "brand_name": "Zaltrap",
    "condition": "Colorectal Cancer",
    "description": "Zaltrap (ziv-aflibercept) is an angiogenesis inhibitor for the combination treatment of patients with metastatic colorectal cancer.",
    "middle_radius": 614,
    "inner_radius": 614
  },
  {
    "x": 2010.4167,
    "y": 100,
    "r": 755,
    "category": 7,
    "company": "Sanofi",
    "dates_clean": "2010-06-17",
    "brand_name": "Jevtana",
    "condition": "Prostate Cancer",
    "description": "Jevtana (cabazitaxel) is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with hormone-refractory metastatic prostate cancer.",
    "middle_radius": 377,
    "inner_radius": 0
  },
  {
    "x": 2016.6667,
    "y": 100,
    "r": 25,
    "category": 8,
    "company": "Sarepta Therapeutics",
    "dates_clean": "2016-09-19",
    "brand_name": "Exondys 51",
    "condition": "Duchenne Muscular Dystrophy",
    "description": "Exondys 51 (eteplirsen) is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.",
    "middle_radius": 4,
    "inner_radius": 4
  },
  {
    "x": 2019.9167,
    "y": 100,
    "r": 25,
    "category": 8,
    "company": "Sarepta Therapeutics",
    "dates_clean": "2019-12-12",
    "brand_name": "Vyondys 53",
    "condition": "Duchenne Muscular Dystrophy",
    "description": "Vyondys 53 (golodirsen) is a phosphordiamidate morpholino oligimer for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation amenable to exon 53 skipping.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2010.6667,
    "y": 100,
    "r": 212,
    "category": 8,
    "company": "Savient Pharmaceuticals",
    "dates_clean": "2010-09-14",
    "brand_name": "Krystexxa",
    "condition": "Gout",
    "description": "Krystexxa (pegloticase) is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy.",
    "middle_radius": 43,
    "inner_radius": 43
  },
  {
    "x": 2011.5833,
    "y": 100,
    "r": 102,
    "category": 7,
    "company": "Seattle Genetics",
    "dates_clean": "2011-08-19",
    "brand_name": "Adcetris",
    "condition": "Lymphoma, Hodgkin's Disease, Mycosis Fungoides",
    "description": "Adcetris (brentuximab vedotin) is a CD30-directed antibody-drug conjugate (ADC) indicated for the treatment of adult patients with previously untreated sALCL or other CD30-expressing PTCL, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone\r\r",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2018.9167,
    "y": 100,
    "r": 124,
    "category": 7,
    "company": "Servier Pharmaceuticals LLC",
    "dates_clean": "2018-12-20",
    "brand_name": "Asparlas",
    "condition": "Acute Lymphoblastic Leukemia",
    "description": "Asparlas (calaspargase pegol-mknl) is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapy regimen for the treatment of acute lymphoblastic leukemia.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2019.5,
    "y": 100,
    "r": 295,
    "category": 3,
    "company": "Shield Therapeutics",
    "dates_clean": "2019-07-25",
    "brand_name": "Accrufer",
    "condition": "Iron Deficiency",
    "description": "Accrufer (ferric maltol) is a non-salt formulation of ferric iron for the treatment of iron deficiency in adults.",
    "middle_radius": 120,
    "inner_radius": 120
  },
  {
    "x": 2019.8333,
    "y": 100,
    "r": 448,
    "category": 6,
    "company": "Shionogi & Co.",
    "dates_clean": "2019-11-14",
    "brand_name": "Fetroja",
    "condition": "Complicated Urinary Tract Infections",
    "description": "Fetroja (cefiderocol) is a siderophore cephalosporin indicated for the treatment of complicated urinary tract infections (cUTI) in patients with limited or no alternative treatment options.",
    "middle_radius": 148,
    "inner_radius": 0
  },
  {
    "x": 2018.5,
    "y": 100,
    "r": 312,
    "category": 3,
    "company": "Shionogi",
    "dates_clean": "2018-07-31",
    "brand_name": "Mulpleta",
    "condition": "Thrombocytopenia",
    "description": "Mulpleta (lusutrombopag) is a once-daily, orally administered, thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a medical or dental procedure.",
    "middle_radius": 155,
    "inner_radius": 155
  },
  {
    "x": 2017.1667,
    "y": 100,
    "r": 1095,
    "category": 2,
    "company": "Shionogi",
    "dates_clean": "2017-03-23",
    "brand_name": "Symproic",
    "condition": "Opioid-Induced Constipation",
    "description": "Symproic (naldemedine) is a peripherally-acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation.",
    "middle_radius": 546,
    "inner_radius": 546
  },
  {
    "x": 2018.9167,
    "y": 100,
    "r": 2484,
    "category": 2,
    "company": "Shire",
    "dates_clean": "2018-12-14",
    "brand_name": "Motegrity",
    "condition": "Chronic Idiopathic Constipation",
    "description": "Motegrity (prucalopride) is a selective serotonin type 4 receptor agonist for the treatment of chronic idiopathic constipation (CIC) in adults.",
    "middle_radius": 1247,
    "inner_radius": 1247
  },
  {
    "x": 2018.5833,
    "y": 100,
    "r": 125,
    "category": 3,
    "company": "Shire",
    "dates_clean": "2018-08-23",
    "brand_name": "Takhzyro",
    "condition": "Hereditary Angioedema",
    "description": "Takhzyro (lanadelumab-flyo) is a plasma kallikrein inhibitor (monoclonal antibody) for the prevention of angioedema attacks in patients with hereditary angioedema.",
    "middle_radius": 41,
    "inner_radius": 41
  },
  {
    "x": 2011.5833,
    "y": 100,
    "r": 218,
    "category": 3,
    "company": "Shire",
    "dates_clean": "2011-08-25",
    "brand_name": "Firazyr",
    "condition": "Angioedema",
    "description": "Firazyr (icatibant) is a selective B2 bradykinin receptor antagonist indicated for the treatment of acute attacks of hereditary angioedema.",
    "middle_radius": 74,
    "inner_radius": 74
  },
  {
    "x": 2010.0833,
    "y": 100,
    "r": 99,
    "category": 2,
    "company": "Shire",
    "dates_clean": "2010-02-26",
    "brand_name": "VPRIV",
    "condition": "Gaucher Disease",
    "description": "VPRIV (velaglucerase alfa) is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with Type 1 Gaucher disease.",
    "middle_radius": 17,
    "inner_radius": 0
  },
  {
    "x": 2016.5,
    "y": 100,
    "r": 2133,
    "category": 10,
    "company": "Shire",
    "dates_clean": "2016-07-11",
    "brand_name": "Xiidra",
    "condition": "Dry Eye Disease",
    "description": "Xiidra (lifitegrast) is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the treatment of the signs and symptoms of dry eye disease.",
    "middle_radius": 1069,
    "inner_radius": 1069
  },
  {
    "x": 2018.5,
    "y": 100,
    "r": 0,
    "category": 6,
    "company": "SIGA Technologies",
    "dates_clean": "2018-07-13",
    "brand_name": "TPOXX",
    "condition": "Smallpox",
    "description": "TPOXX (tecovirimat) is an orthopoxvirus-specific antiviral indicated for the treatment of human smallpox disease.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2019.8333,
    "y": 100,
    "r": 655,
    "category": 1,
    "company": "SK Life Science",
    "dates_clean": "2019-11-21",
    "brand_name": "Xcopri",
    "condition": "Seizures",
    "description": "Xcopri (cenobamate) is an antiepileptic drug for the treatment of partial-onset seizures in adult patients.",
    "middle_radius": 214,
    "inner_radius": 214
  },
  {
    "x": 2014.5,
    "y": 100,
    "r": 120,
    "category": 7,
    "company": "Spectrum Pharmaceuticals",
    "dates_clean": "2014-07-03",
    "brand_name": "Beleodaq",
    "condition": "Peripheral T-cell Lymphoma",
    "description": "Beleodaq (belinostat) is a histone deacetylase (HDAC) inhibitor for the treatment of peripheral T-cell lymphoma (PTCL).",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2015.5833,
    "y": 100,
    "r": 2375,
    "category": 10,
    "company": "Sprout Pharmaceuticals",
    "dates_clean": "2015-08-18",
    "brand_name": "Addyi",
    "condition": "Hypoactive Sexual Desire Disorder",
    "description": "Addyi (flibanserin) is a non-hormonal, multifunctional serotonin agonist antagonist (MSAA) for the treatment of hypoactive sexual desire disorder in premenopausal women.",
    "middle_radius": 1198,
    "inner_radius": 1198
  },
  {
    "x": 2018.9167,
    "y": 100,
    "r": 28,
    "category": 7,
    "company": "Stemline Therapeutics",
    "dates_clean": "2018-12-21",
    "brand_name": "Elzonris",
    "condition": "Blastic Plasmacytoid Dendritic Cell Neoplasm",
    "description": "Elzonris (tagraxofusp-erzs) is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2018.1667,
    "y": 100,
    "r": 926,
    "category": 7,
    "company": "Sun Pharmaceutical Industries",
    "dates_clean": "2018-03-20",
    "brand_name": "Ilumya",
    "condition": "Plaque Psoriasis",
    "description": "Ilumya (tildrakizumab-asmn) is a humanized, anti-IL-23p19 monoclonal antibody for the treatment of moderate-to-severe plaque psoriasis.",
    "middle_radius": 310,
    "inner_radius": 310
  },
  {
    "x": 2013.8333,
    "y": 100,
    "r": 1133,
    "category": 1,
    "company": "Sunovion Pharmaceuticals",
    "dates_clean": "2013-11-08",
    "brand_name": "Aptiom",
    "condition": "Epilepsy, Seizures",
    "description": "Aptiom (eslicarbazepine acetate) is a voltage-gated sodium channel blocker for the treatment of partial-onset seizures in patients with epilepsy.",
    "middle_radius": 406,
    "inner_radius": 406
  },
  {
    "x": 2017.6667,
    "y": 100,
    "r": 288,
    "category": 10,
    "company": "Symbiomix Therapeutics",
    "dates_clean": "2017-09-15",
    "brand_name": "Solosec",
    "condition": "Bacterial Vaginosis",
    "description": "Solosec (secnidazole) is a nitroimidazole antimicrobial for use as a single-dose oral therapy in the treatment of bacterial vaginosis (BV).",
    "middle_radius": 119,
    "inner_radius": 119
  },
  {
    "x": 2017,
    "y": 100,
    "r": 1775,
    "category": 2,
    "company": "Synergy Pharmaceuticals",
    "dates_clean": "2017-01-19",
    "brand_name": "Trulance",
    "condition": "Constipation -- Chronic, Irritable Bowel Syndrome",
    "description": "Trulance (plecanatide) is a guanylate cyclase-C agonist for the treatment of chronic idiopathic constipation, and irritable bowel syndrome with constipation (IBS-C).",
    "middle_radius": 892,
    "inner_radius": 892
  },
  {
    "x": 2015.6667,
    "y": 100,
    "r": 800,
    "category": 7,
    "company": "Taiho Oncology",
    "dates_clean": "2015-09-22",
    "brand_name": "Lonsurf",
    "condition": "Colorectal Cancer, Gastric Cancer",
    "description": "Lonsurf (tipiracil and trifluridine) is a thymidine phosphorylase inhibitor and nucleoside metabolic inhibitor combination indicated for the treatment of patients with previously treated metastatic colorectal cancer, and previously treated metastatic gastric or gastroesophageal junction adenocarcinoma.",
    "middle_radius": 266,
    "inner_radius": 266
  },
  {
    "x": 2018.1667,
    "y": 100,
    "r": 40,
    "category": 6,
    "company": "TaiMed Biologics USA Corp.",
    "dates_clean": "2018-03-06",
    "brand_name": "Trogarzo",
    "condition": "HIV Infection",
    "description": "Trogarzo (ibalizumab-uiyk) is a CD4-directed post-attachment HIV-1 inhibitor for the treatment of multidrug resistant human immunodeficiency virus-1 (HIV-1) infection in heavily treatment-experienced adults.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2017.25,
    "y": 100,
    "r": 222,
    "category": 7,
    "company": "Takeda",
    "dates_clean": "2017-04-28",
    "brand_name": "Alunbrig",
    "condition": "Non-Small Cell Lung Cancer",
    "description": "Alunbrig (brigatinib) is an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) non-small cell cancer (NSCLC) whose disease is resistant to crizotinib.\r\r",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2015.8333,
    "y": 100,
    "r": 722,
    "category": 7,
    "company": "Takeda",
    "dates_clean": "2015-11-20",
    "brand_name": "Ninlaro",
    "condition": "Multiple Myeloma",
    "description": "Ninlaro (ixazomib) is an oral proteasome inhibitor indicated for use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.",
    "middle_radius": 362,
    "inner_radius": 362
  },
  {
    "x": 2014.3333,
    "y": 100,
    "r": 1612,
    "category": 7,
    "company": "Takeda",
    "dates_clean": "2014-05-20",
    "brand_name": "Entyvio",
    "condition": "Crohn's Disease -- Acute, Ulcerative Colitis",
    "description": "Entyvio (vedolizumab) is an integrin receptor antagonist for the treatment of Crohn's disease and ulcerative colitis.",
    "middle_radius": 733,
    "inner_radius": 733
  },
  {
    "x": 2011.0833,
    "y": 100,
    "r": 5941,
    "category": 4,
    "company": "Takeda",
    "dates_clean": "2011-02-25",
    "brand_name": "Edarbi",
    "condition": "Hypertension",
    "description": "Edarbi (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) for the treatment of hypertension.",
    "middle_radius": 2269,
    "inner_radius": 801
  },
  {
    "x": 2013,
    "y": 100,
    "r": 4227,
    "category": 2,
    "company": "Takeda",
    "dates_clean": "2013-01-25",
    "brand_name": "Nesina",
    "condition": "Diabetes Type 2",
    "description": "Nesina (alogliptin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes.",
    "middle_radius": 1846,
    "inner_radius": 712
  },
  {
    "x": 2013.6667,
    "y": 100,
    "r": 2092,
    "category": 1,
    "company": "Takeda",
    "dates_clean": "2013-09-30",
    "brand_name": "Trintellix",
    "condition": "Depression",
    "description": "Trintellix (vortioxetine) is a multimodal antidepressant for the treatment of major depressive disorder (MDD).",
    "middle_radius": 855,
    "inner_radius": 855
  },
  {
    "x": 2019.5833,
    "y": 100,
    "r": 107,
    "category": 6,
    "company": "TB Alliance",
    "dates_clean": "2019-08-14",
    "brand_name": "pretomanid",
    "condition": "Tuberculosis -- Resistant",
    "description": "Pretomanid is a nitroimidazooxazine antimycobacterial indicated for use in combination with bedaquiline and linezolid (the BPaL regimen) for the treatment of adults with pulmonary extensively drug resistant (XDR), treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2015.6667,
    "y": 100,
    "r": 1087,
    "category": 2,
    "company": "Tesaro",
    "dates_clean": "2015-09-01",
    "brand_name": "Varubi",
    "condition": "Nausea/Vomiting -- Chemotherapy Induced",
    "description": "Varubi (rolapitant) is a substance P/neurokinin 1 (NK1) receptor antagonist indicated for use in the prevention of delayed nausea and vomiting associated with emetogenic chemotherapy.",
    "middle_radius": 543,
    "inner_radius": 0
  },
  {
    "x": 2017.1667,
    "y": 100,
    "r": 553,
    "category": 7,
    "company": "Tesaro",
    "dates_clean": "2017-03-27",
    "brand_name": "Zejula",
    "condition": "Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer",
    "description": "Zejula (niraparib) is an oral, poly ADP-ribose polymerase (PARP) inhibitor for the treatment of patients with ovarian, fallopian tube, or primary peritoneal cancer.",
    "middle_radius": 181,
    "inner_radius": 181
  },
  {
    "x": 2018.5833,
    "y": 100,
    "r": 846,
    "category": 6,
    "company": "Tetraphase Pharmaceuticals",
    "dates_clean": "2018-08-27",
    "brand_name": "Xerava",
    "condition": "Complicated Intra-Abdominal Infections",
    "description": "Xerava (eravacycline) is a fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections.",
    "middle_radius": 431,
    "inner_radius": 0
  },
  {
    "x": 2018.6667,
    "y": 100,
    "r": 1986,
    "category": 1,
    "company": "Teva",
    "dates_clean": "2018-09-14",
    "brand_name": "Ajovy",
    "condition": "Migraine Prophylaxis",
    "description": "Ajovy (fremanezumab) is a fully-humanized monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) ligand indicated for the preventive treatment of migraine.",
    "middle_radius": 661,
    "inner_radius": 661
  },
  {
    "x": 2017.25,
    "y": 100,
    "r": 90,
    "category": 1,
    "company": "Teva",
    "dates_clean": "2017-04-03",
    "brand_name": "Austedo",
    "condition": "Huntington Disease, Tardive Dyskinesia",
    "description": "Austedo (deutetrabenazine) is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of chorea associated with Huntingtonäó»s disease and the treatment of tardive dyskinesia.",
    "middle_radius": 45,
    "inner_radius": 45
  },
  {
    "x": 2016.1667,
    "y": 100,
    "r": 1657,
    "category": 9,
    "company": "Teva",
    "dates_clean": "2016-03-23",
    "brand_name": "Cinqair",
    "condition": "Asthma",
    "description": "Cinqair (reslizumab) is an interleukin 5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on maintenance treatment of patients with eosinophilic asthma.",
    "middle_radius": 829,
    "inner_radius": 829
  },
  {
    "x": 2012.75,
    "y": 100,
    "r": 111,
    "category": 7,
    "company": "Teva",
    "dates_clean": "2012-10-26",
    "brand_name": "Synribo",
    "condition": "Chronic Myelogenous Leukemia",
    "description": "Synribo (omacetaxine mepesuccinate) is a first-in-class small molecule drug for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2015.4167,
    "y": 100,
    "r": 10942,
    "category": 3,
    "company": "The Medicines Company",
    "dates_clean": "2015-06-22",
    "brand_name": "Kengreal",
    "condition": "Percutaneous Coronary Intervention",
    "description": "Kengreal (cangrelor) is an intravenous P2Y12 platelet inhibitor indicated for use in patients undergoing Percutaneous Coronary Intervention (PCI) to reduce the risk of periprocedural thrombotic events.",
    "middle_radius": 5470,
    "inner_radius": 0
  },
  {
    "x": 2014.5833,
    "y": 100,
    "r": 1959,
    "category": 6,
    "company": "The Medicines Company",
    "dates_clean": "2014-08-06",
    "brand_name": "Orbactiv",
    "condition": "Skin and Structure Infection",
    "description": "Orbactiv (oritavancin) is a semi-synthetic lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI).",
    "middle_radius": 981,
    "inner_radius": 0
  },
  {
    "x": 2018.5833,
    "y": 100,
    "r": 2308,
    "category": 10,
    "company": "The Population Council",
    "dates_clean": "2018-08-10",
    "brand_name": "Annovera",
    "condition": "Contraception",
    "description": "Annovera (ethinyl estradiol and segesterone acetate) is an estrogen and progestin vaginal contraceptive system indicated to prevent pregnancy for up to a year.",
    "middle_radius": 0,
    "inner_radius": 0
  },
  {
    "x": 2010.8333,
    "y": 100,
    "r": 806,
    "category": 10,
    "company": "Theratechnologies",
    "dates_clean": "2010-11-10",
    "brand_name": "Egrifta",
    "condition": "Reduction of Excess Abdominal Fat in HIV-Infected Patients with Lipodystrophy",
    "description": "Egrifta (tesamorelin) is a synthetic analogue of growth hormone releasing factor (GRF) for the treatment of excess abdominal fat in HIV patients with lipodystrophy.",
    "middle_radius": 263,
    "inner_radius": 263
  },
  {
    "x": 2018.8333,
    "y": 100,
    "r": 812,
    "category": 9,
    "company": "Theravance Biopharma",
    "dates_clean": "2018-11-09",
    "brand_name": "Yupelri",
    "condition": "Chronic Obstructive Pulmonary Disease",
    "description": "Yupelri (revefenacin) is a long-acting muscarinic antagonist (LAMA) for the treatment of chronic obstructive pulmonary disease (COPD).",
    "middle_radius": 417,
    "inner_radius": 417
  },
  {
    "x": 2012.75,
    "y": 100,
    "r": 652,
    "category": 10,
    "company": "ThromboGenics NV",
    "dates_clean": "2012-10-17",
    "brand_name": "Jetrea",
    "condition": "Vitreomacular Adhesion",
    "description": "Jetrea (ocriplasmin) is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion.",
    "middle_radius": 188,
    "inner_radius": 188
  },
  {
    "x": 2011.3333,
    "y": 100,
    "r": 1368,
    "category": 6,
    "company": "Tibotec Pharmaceuticals",
    "dates_clean": "2011-05-20",
    "brand_name": "Edurant",
    "condition": "HIV Infection",
    "description": "Edurant (rilpivirine) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated in combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults who have never taken HIV therapy (treatment-naí¿ve).",
    "middle_radius": 682,
    "inner_radius": 0
  },
  {
    "x": 2016.0833,
    "y": 100,
    "r": 1256,
    "category": 1,
    "company": "UCB",
    "dates_clean": "2016-02-19",
    "brand_name": "Briviact",
    "condition": "Epilepsy",
    "description": "Briviact (brivaracetam) is a selective, high-affinity synaptic vesicle protein 2A ligand and analog of levetiracetam indicated for the treatment of partial-onset seizures in patients with epilepsy.",
    "middle_radius": 455,
    "inner_radius": 455
  },
  {
    "x": 2018.25,
    "y": 100,
    "r": 187,
    "category": 8,
    "company": "Ultragenyx Pharmaceutical",
    "dates_clean": "2018-04-17",
    "brand_name": "Crysvita",
    "condition": "X-Linked Hypophosphatemia",
    "description": "Crysvita (burosumab-twza) is a fibroblast growth factor 23 (FGF23) blocking antibody for the treatment of x-linked hypophosphatemia (XLH).",
    "middle_radius": 66,
    "inner_radius": 66
  },
  {
    "x": 2017.8333,
    "y": 100,
    "r": 27,
    "category": 2,
    "company": "Ultragenyx Pharmaceutical",
    "dates_clean": "2017-11-15",
    "brand_name": "Mepsevii",
    "condition": "Mucopolysaccharidosis Type VII",
    "description": "Mepsevii (vestronidase alfa) is a recombinant human lysosomal beta glucuronidase indicated for the treatment of Mucopolysaccharidosis VII (MPS VII, Sly syndrome).",
    "inner_radius": 12
  },
  {
    "x": 2015.1667,
    "y": 100,
    "r": 226,
    "category": 7,
    "company": "United Therapeutics",
    "dates_clean": "2015-03-10",
    "brand_name": "Unituxin",
    "condition": "Neuroblastoma",
    "description": "Unituxin (dinutuximab) is a chimeric monoclonal antibody used for the treatment of pediatric neuroblastoma.",
    "middle_radius": 113,
    "inner_radius": 0
  },
  {
    "x": 2018.3333,
    "y": 100,
    "r": 866,
    "category": 1,
    "company": "US WorldMeds",
    "dates_clean": "2018-05-16",
    "brand_name": "Lucemyra",
    "condition": "Opiate Withdrawal",
    "description": "Lucemyra (lofexidine hydrochloride) is a selective alpha 2-adrenergic receptor agonist indicated for reducing the severity of withdrawal symptoms in patients experiencing opioid withdrawal.",
    "middle_radius": 281,
    "inner_radius": 281
  },
  {
    "x": 2017.8333,
    "y": 100,
    "r": 840,
    "category": 10,
    "company": "Valeant",
    "dates_clean": "2017-11-02",
    "brand_name": "Vyzulta",
    "condition": "Glaucoma (Open Angle), Intraocular Hypertension",
    "description": "Vyzulta (latanoprostene bunod) is a nitric oxide donating prostaglandin receptor agonist for the treatment of patients with open angle glaucoma or ocular hypertension.",
    "middle_radius": 271,
    "inner_radius": 0
  },
  {
    "x": 2017.0833,
    "y": 100,
    "r": 2915,
    "category": 7,
    "company": "Valeant",
    "dates_clean": "2017-02-15",
    "brand_name": "Siliq",
    "condition": "Plaque Psoriasis",
    "description": "Siliq (brodalumab) is a human anti-interleukin-17-receptor monoclonal antibody for the treatment of plaque psoriasis.",
    "middle_radius": 1457,
    "inner_radius": 844
  },
  {
    "x": 2014.4167,
    "y": 100,
    "r": 1651,
    "category": 5,
    "company": "Valeant",
    "dates_clean": "2014-06-06",
    "brand_name": "Jublia",
    "condition": "Onychomycosis -- Toenail",
    "description": "Jublia (efinaconazole) is a topical triazole antifungal for the treatment of onychomycosis of the toenails.",
    "middle_radius": 415,
    "inner_radius": 415
  },
  {
    "x": 2013.8333,
    "y": 100,
    "r": 423,
    "category": 5,
    "company": "Valeant",
    "dates_clean": "2013-11-14",
    "brand_name": "Luzu",
    "condition": "Tinea Corporis, Tinea Pedis, Tinea Cruris",
    "description": "Luzu (luliconazole) Cream  is an azole antifungal indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis.",
    "middle_radius": 210,
    "inner_radius": 210
  },
  {
    "x": 2014,
    "y": 100,
    "r": 124,
    "category": 1,
    "company": "Vanda Pharmaceuticals",
    "dates_clean": "2014-01-31",
    "brand_name": "Hetlioz",
    "condition": "Non-24-Hour Disorder",
    "description": "Hetlioz (tasimelteon) is a melatonin receptor agonist for the treatment of Non-24-Hour Disorder in the totally blind.",
    "middle_radius": 62,
    "inner_radius": 62
  },
  {
    "x": 2018.6667,
    "y": 100,
    "r": 279,
    "category": 7,
    "company": "Verastem",
    "dates_clean": "2018-09-24",
    "brand_name": "Copiktra",
    "condition": "Chronic Lymphocytic Leukemia, Follicular Lymphoma",
    "description": "Copiktra (duvelisib) is a first-in-class, oral, dual phosphoinositide-3-kinase (PI3K)-delta/PI3K-gamma inhibitor for the treatment relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and relapsed or refractory follicular lymphoma (FL).",
    "middle_radius": 101,
    "inner_radius": 0
  },
  {
    "x": 2019.75,
    "y": 100,
    "r": 510,
    "category": 9,
    "company": "Vertex",
    "dates_clean": "2019-10-21",
    "brand_name": "Trikafta",
    "condition": "Cystic Fibrosis",
    "description": "Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) is a triple combination regimen for the treatment of cystic fibrosis (CF) in patients ages 12 years and older who have at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.",
    "middle_radius": 255,
    "inner_radius": 203
  },
  {
    "x": 2018.0833,
    "y": 100,
    "r": 1150,
    "category": 9,
    "company": "Vertex",
    "dates_clean": "2018-02-12",
    "brand_name": "Symdeko",
    "condition": "Cystic Fibrosis",
    "description": "Symdeko (ivacaftor/tezacaftor tablets and ivacaftor tablets) is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator and CFTR corrector combination for the treatment of cystic fibrosis in patients aged 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the CFTR) gene that is responsive to Symdeko.",
    "middle_radius": 658,
    "inner_radius": 502
  },
  {
    "x": 2015.5,
    "y": 100,
    "r": 740,
    "category": 9,
    "company": "Vertex",
    "dates_clean": "2015-07-02",
    "brand_name": "Orkambi",
    "condition": "Cystic Fibrosis",
    "description": "Orkambi (ivacaftor and lumacaftor) is a CFTR potentiator and CFTR corrector combination for the treatment of the underlying cause of cystic fibrosis in patients 2 years and older with two copies of the F508del mutation in their CFTR gene.",
    "middle_radius": 371,
    "inner_radius": 371
  },
  {
    "x": 2012,
    "y": 100,
    "r": 213,
    "category": 9,
    "company": "Vertex",
    "dates_clean": "2012-01-31",
    "brand_name": "Kalydeco",
    "condition": "Cystic Fibrosis",
    "description": "Kalydeco (ivacaftor) is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients ages 6 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor.",
    "middle_radius": 104,
    "inner_radius": 104
  },
  {
    "x": 2011.3333,
    "y": 100,
    "r": 354,
    "category": 6,
    "company": "Vertex",
    "dates_clean": "2011-05-23",
    "brand_name": "Incivek",
    "condition": "Chronic Hepatitis C",
    "description": "Incivek (telaprevir) is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated, in combination with peginterferon alfa and ribavirin, for the treatment of chronic hepatitis C (CHC).",
    "middle_radius": 68,
    "inner_radius": 0
  },
  {
    "x": 2013.5833,
    "y": 100,
    "r": 1641,
    "category": 6,
    "company": "ViiV Healthcare",
    "dates_clean": "2013-08-12",
    "brand_name": "Tivicay",
    "condition": "HIV Infection",
    "description": "Tivicay (dolutegravir) is an integrase inhibitor indicated for use in combination with other antiretroviral (ARV) agents for the treatment of HIV-1.",
    "middle_radius": 824,
    "inner_radius": 0
  },
  {
    "x": 2012.25,
    "y": 100,
    "r": 1001,
    "category": 10,
    "company": "Vivus",
    "dates_clean": "2012-04-27",
    "brand_name": "Stendra",
    "condition": "Erectile Dysfunction",
    "description": "Stendra (avanafil) is a phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED).",
    "middle_radius": 282,
    "inner_radius": 282
  },
  {
    "x": 2015.6667,
    "y": 100,
    "r": 4,
    "category": 2,
    "company": "Wellstat Therapeutics",
    "dates_clean": "2015-09-04",
    "brand_name": "Xuriden",
    "condition": "Hereditary Orotic Aciduria",
    "description": "Xuriden (uridine triacetate) is an orally administered pyrimidine analog uridine replacement product for the treatment of patients with hereditary orotic aciduria.",
    "middle_radius": 0,
    "inner_radius": 0
  }
];
